var title_f24_24_24960="Streptobacillus moniliformis";
var content_f24_24_24960=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Streptobacillus moniliformis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 230px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pleomorphic filamentous bacilli with characteristic bulbous swelling arranged in chains and tangled clumps on Gram's stain (x 1000).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Torres, A, Cuende, E, De Pablos, M, et al. Remitting seronegative symmetrical synovitis with pitting edema associated with subcutaneous streptobacillus moniliformis abscess. J Rheumatol 2001; 28:1696. Copyright &copy; 2001 Journal of Rheumatology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_24_24960=[""].join("\n");
var outline_f24_24_24960=null;
var title_f24_24_24961="Patient information: Shock (The Basics)";
var content_f24_24_24961=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?23/60/24515\">",
"         Patient information: GI bleed (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/50/33569\">",
"         Patient information: Sepsis in adults (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Shock (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/shock-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H28464817\">",
"      <span class=\"h1\">",
"       What is shock?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Shock is a condition that happens when blood pressure is low and not enough blood gets to the body&rsquo;s organs and tissues. This can cause confusion and other symptoms.",
"     </p>",
"     <p>",
"      Shock is a life-threatening condition. A person in shock needs treatment right away. Without treatment, the organs in the body will stop working. This causes death.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28464832\">",
"      <span class=\"h1\">",
"       What are the symptoms of shock?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms depend on the cause of the shock and how severe it is. The main symptoms of shock include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Low blood pressure &ndash; If you take the person&rsquo;s pulse, it might feel weak.",
"       </li>",
"       <li>",
"        Fast heart rate",
"       </li>",
"       <li>",
"        Acting differently from normal. This can include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Acting excited or confused &ndash; A person in shock might have trouble paying attention to instructions, or not realize where he or she is.",
"       </li>",
"       <li>",
"        Not responding when someone talks to them",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Cool clammy skin or red, flushed skin",
"       </li>",
"       <li>",
"        Urinating much less than usual",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Shock can also cause other symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28464847\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, as soon as possible. Many people who are in shock are already in a hospital. If you are not in a hospital, you or someone with you should call the doctor or nurse if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You have an injury or infection and any of the main symptoms of shock.",
"       </li>",
"       <li>",
"        Had a recent surgery or hospital stay, and now are sick or have an infection.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If your doctor or nurse cannot see you right away, or you cannot reach him or her, go to the nearest emergency room. If you have a serious injury, such as a broken leg or bleeding wound, call 9-1-1 right away.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28464862\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor or nurse will do tests to find the cause of the shock. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Urine tests",
"       </li>",
"       <li>",
"        Imaging tests, such as X-rays, CT scans, or ultrasound &ndash; These imaging tests create pictures of the inside of the body.",
"       </li>",
"       <li>",
"        Heart tests - These can include a test called an &ldquo;electrocardiogram&rdquo; or &ldquo;ECG&rdquo; and a test called an &ldquo;echocardiogram.&rdquo; These tests can show heart problems that could cause shock.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28464879\">",
"      <span class=\"h1\">",
"       How is shock treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment for shock depends on the cause. Treatments can include: &nbsp;",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Treatments to stop bleeding &ndash; If the shock is caused by bleeding, doctors and nurses can put pressure on the area that is bleeding or sew it up.",
"       </li>",
"       <li>",
"        Fluids that go into a vein through a thin tube called an &ldquo;IV&rdquo;",
"       </li>",
"       <li>",
"        Blood transfusion &ndash; This is when a person gets blood that was donated by someone else. The blood goes into a vein.",
"       </li>",
"       <li>",
"        Treatments to get rid of fluid, air, or blood in the belly or around the heart or lungs &ndash; Doctors can use a thin needle to take it out, or do surgery.",
"       </li>",
"       <li>",
"        Emergency surgery &ndash; This can treat injuries that cause shock.",
"       </li>",
"       <li>",
"        Antibiotics that go into a vein through an IV &ndash; This can treat infections that cause shock.",
"       </li>",
"       <li>",
"        Medicines to increase blood pressure while doctors treat the cause of shock",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28464894\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33569?source=see_link\">",
"       Patient information: Sepsis in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/60/24515?source=see_link\">",
"       Patient information: GI bleed (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?24/24/24961?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83175 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-6B4A64F196-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_24_24961=[""].join("\n");
var outline_f24_24_24961=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28464817\">",
"      What is shock?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28464832\">",
"      What are the symptoms of shock?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28464847\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28464862\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28464879\">",
"      How is shock treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28464894\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/60/24515?source=related_link\">",
"      Patient information: GI bleed (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33569?source=related_link\">",
"      Patient information: Sepsis in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_24_24962="Dipyridamole stress and outcome";
var content_f24_24_24962=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Defect size with dipyridamole MPI predicts cardiac events",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a study of 512 patients followed for a mean of 13 months after dipyridamole myocardial perfusion imaging (MPI), the annual rate of cardiac events (cardiac death, nonfatal myocardial infarction) and cardiac-related hospital admissions (heart failure, unstable angina pectoris, revascularization) progressively increases in relation to defect size (small, moderate, large).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Heller, GV, Herman, SD, Travin, MI, et al, J Am Coll Cardiol 1995; 26:1202.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_24_24962=[""].join("\n");
var outline_f24_24_24962=null;
var title_f24_24_24963="Dermatophytid reaction";
var content_f24_24_24963=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F63421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F63421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermatophytid reaction (autoeczematization or id reaction due to dermatophyte infection)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A widespread eczematous eruption primarily distributed on the face, neck, and ears developed in this child with tinea capitis. The terms autoeczematization and id reaction are also used to refer to this phenomenon.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Bernard Cohen, MD, Dermatlas;",
"     <a href=\"file://www.dermatlas.org\" target=\"_blank\">",
"      file://www.dermatlas.org",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_24_24963=[""].join("\n");
var outline_f24_24_24963=null;
var title_f24_24_24964="Potassium phosphate and sodium phosphate: Patient drug information";
var content_f24_24_24964=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Potassium phosphate and sodium phosphate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/17/7444?source=see_link\">",
"     see \"Potassium phosphate and sodium phosphate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/3/37940?source=see_link\">",
"     see \"Potassium phosphate and sodium phosphate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F212118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      K-Phos&reg; MF;",
"     </li>",
"     <li>",
"      K-Phos&reg; Neutral;",
"     </li>",
"     <li>",
"      K-Phos&reg; No. 2;",
"     </li>",
"     <li>",
"      Phos-NaK;",
"     </li>",
"     <li>",
"      Phospha 250&trade; Neutral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691518",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat low phosphate levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702774",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to potassium phosphate, sodium phosphate, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703215",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Addison's disease, very bad kidney disease, kidney stone, high phosphate levels, or high potassium levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696686",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid salt substitutes that have potassium, potassium-sparing diuretics, or potassium products.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694382",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Add contents of packet to",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        2",
"       </sub>",
"       cup of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12102 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-CAE323FBD7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_24_24964=[""].join("\n");
var outline_f24_24_24964=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212118\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012668\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012667\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012672\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012673\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012675\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012670\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012671\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012676\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012677\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/17/7444?source=related_link\">",
"      Potassium phosphate and sodium phosphate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/3/37940?source=related_link\">",
"      Potassium phosphate and sodium phosphate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_24_24965="Ondansetron: Patient drug information";
var content_f24_24_24965=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ondansetron: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     see \"Ondansetron: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=see_link\">",
"     see \"Ondansetron: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F203706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zofran&reg;;",
"     </li>",
"     <li>",
"      Zofran&reg; ODT;",
"     </li>",
"     <li>",
"      Zuplenz&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F203707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Ondansetron&reg;;",
"     </li>",
"     <li>",
"      CO Ondansetron;",
"     </li>",
"     <li>",
"      Dom-Ondansetron;",
"     </li>",
"     <li>",
"      JAMP-Ondansetron;",
"     </li>",
"     <li>",
"      Mint-Ondansetron;",
"     </li>",
"     <li>",
"      Mylan-Ondansetron;",
"     </li>",
"     <li>",
"      Ondansetron Injection;",
"     </li>",
"     <li>",
"      Ondansetron Injection USP;",
"     </li>",
"     <li>",
"      Ondansetron-Odan;",
"     </li>",
"     <li>",
"      Ondansetron-Omega;",
"     </li>",
"     <li>",
"      PHL-Ondansetron;",
"     </li>",
"     <li>",
"      PMS-Ondansetron;",
"     </li>",
"     <li>",
"      RAN&trade;-Ondansetron;",
"     </li>",
"     <li>",
"      ratio-Ondansetron;",
"     </li>",
"     <li>",
"      Sandoz-Ondansetron;",
"     </li>",
"     <li>",
"      Teva-Ondansetron;",
"     </li>",
"     <li>",
"      Zofran&reg;;",
"     </li>",
"     <li>",
"      Zofran&reg; ODT;",
"     </li>",
"     <li>",
"      ZYM-Ondansetron",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691522",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat upset stomach and throwing up.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ondansetron or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a heart problem called congenital QT syndrome, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697142",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a slow heartbeat, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697138",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a low potassium or magnesium level, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696427",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A faster, harmful heartbeat may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696140",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To stop upset stomach from chemo, take 30 minutes before chemo.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To stop upset stomach from radiation, take 1 to 2 hours before care.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705488",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral-disintegrating tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695516",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place on your tongue and let it melt. Water is not needed. Do not swallow it whole. Do not chew, break, or crush it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2928439",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral film:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2893439",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Open right before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2934439",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put film on tongue and let it melt. Water in not needed. If using more than 1 film, let each film melt all the way before using the next film.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10926 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-F93BED5DA7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_24_24965=[""].join("\n");
var outline_f24_24_24965=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203706\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203707\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020618\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020620\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020619\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020624\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020625\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020627\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020622\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020623\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020628\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020629\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=related_link\">",
"      Ondansetron: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=related_link\">",
"      Ondansetron: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_24_24966="Clinical manifestations and initial management of infants with bladder exstrophy";
var content_f24_24_24966=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and initial management of infants with bladder exstrophy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/24/24966/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/24/24966/contributors\">",
"     Joseph G Borer, MD, FAAP, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/24/24966/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/24/24966/contributors\">",
"     Laurence S Baskin, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/24/24966/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/24/24966/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/24/24966/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder exstrophy is a complex congenital anomaly involving the musculoskeletal system and the urinary, reproductive, and intestinal tracts. It is one of three disorders within the exstrophy-epispadias complex.",
"   </p>",
"   <p>",
"    The diagnosis, clinical features, and initial management of bladder exstrophy are reviewed here. The surgical management and postoperative care of children with bladder exstrophy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11849?source=see_link\">",
"     \"Surgical management and postoperative outcome of children with bladder exstrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EXSTROPHY-EPISPADIAS COMPLEX",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exstrophy-epispadias complex (EEC) encompasses the following congenital anomalies, including bladder exstrophy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epispadias, the least severe defect of the group, is characterized by an exposed or open dorsal urethra.",
"     </li>",
"     <li>",
"      Bladder exstrophy is classically characterized by an open, inside out bladder (the inner surface exposed) and exposed dorsal urethra on the surface of the lower abdominal wall (",
"      <a class=\"graphic graphic_picture graphicRef73750 \" href=\"UTD.htm?16/33/16914\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef53828 \" href=\"UTD.htm?22/46/23267\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef59654 \" href=\"UTD.htm?27/26/28079\">",
"       picture 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef58943 \" href=\"UTD.htm?19/15/19696\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Cloacal exstrophy, the most severe defect, is classically characterized by exstrophy of the urinary bladder and large intestine (hindgut) through an abdominal wall defect, anal atresia, hypoplasia of the colon, omphalocele, and anomalous genitalia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6488?source=see_link\">",
"       \"Obstetrical and neonatal management of body stalk anomalies and cloacal abnormalities\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A large case series of 411 patients from North America and Europe reported maternal smoking and medical radiation during the third trimester were associated with cloacal exstrophy (most severe defect), whereas periconceptional",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/31/22005?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation prevented the most severe defects [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24966/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of bladder exstrophy appears to be due to an embryological defect in the abdominal wall development. The most universally accepted theory proposed by Marshall and Muecke is that lower abdominal wall development is disrupted by the overdevelopment of the cloacal membrane, which prevents medial migration of the mesenchymal tissue towards the midline [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24966/abstract/2\">",
"     2",
"    </a>",
"    ]. The subsequent rupture of the cloacal membrane results in herniation of the lower abdominal components to the surface of the lower abdominal wall and the characteristic features of the exstrophy-epispadias complex. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Exstrophy-epispadias complex'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of bladder exstrophy ranges from 3.3 to 5 per 100,000 live births (ie, 1 per 20,000 to 33,000 live births) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24966/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. It occurs 1.5 to 2.5 times more often in males than females [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24966/abstract/3,5\">",
"     3,5",
"    </a>",
"    ] and is more frequent in first born children as well as in white compared to nonwhite infants [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24966/abstract/6\">",
"     6",
"    </a>",
"    ]. There appears to be a genetic predisposition, as the risk of bladder exstrophy increases in offspring of affected individuals to 1 in 70 live births, about a 500-fold greater incidence than the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24966/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with classic bladder exstrophy, also referred to as vesica ectopia, typically have a constellation of findings that affect the abdominal wall, pelvic bones, anus, and genitalia (",
"    <a class=\"graphic graphic_picture graphicRef73750 \" href=\"UTD.htm?16/33/16914\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef53828 \" href=\"UTD.htm?22/46/23267\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef59654 \" href=\"UTD.htm?27/26/28079\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef58943 \" href=\"UTD.htm?19/15/19696\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Open bladder plate and exposed posterior urethra &mdash; The triangular defect caused by the premature rupture of the abnormal cloacal membrane contains the exstrophied bladder and exposed urethra.",
"     </li>",
"     <li>",
"      Low set umbilicus &mdash; The umbilicus lies just above the apex of the defect in a more caudal position than normal.",
"     </li>",
"     <li>",
"      Diastasis of the symphysis pubis &mdash; Diastasis of the symphysis pubis is caused by outward malrotation of the pelvic bones, more specifically the innominate bones (ilium, ischium, and pubis) that form the acetabulum. This results in the widening or separation of the pubic bones from the anterior midline (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef55640 \" href=\"UTD.htm?19/50/20257\">",
"       image 1",
"      </a>",
"      ). Other findings include an increased distance between the hips and outward rotation of the acetabula and lower limbs [",
"      <a class=\"abstract\" href=\"UTD.htm?24/24/24966/abstract/8\">",
"       8",
"      </a>",
"      ]. In one study, computerized tomography demonstrated greater external rotation of both the iliac wing angle and sacroiliac joint angle in children with bladder exstrophy compared to age and gender-matched controls [",
"      <a class=\"abstract\" href=\"UTD.htm?24/24/24966/abstract/9\">",
"       9",
"      </a>",
"      ]. Other findings included a greater mean pubic diastasis (4.2 versus 0.6 cm) and an increase in inferior rotation in patients with bladder exstrophy compared to controls. These deformities, if not corrected, may result in an abnormal gait in affected children.",
"     </li>",
"     <li>",
"      Anteriorly displaced anus &mdash; The perineum is short and broad with displacement of the anus anteriorly, directly behind the urogenital diaphragm, which demarcates the posterior limit of the triangular fascial defect [",
"      <a class=\"abstract\" href=\"UTD.htm?24/24/24966/abstract/10\">",
"       10",
"      </a>",
"      ]. The anterior anal displacement and associated abnormalities in the pelvic floor musculature predispose patients with bladder exstrophy to fecal incontinence and rectal prolapse, and are important considerations for surgical correction. However, surgical reconstruction of this component of the anatomical defects present in bladder exstrophy is usually unnecessary.",
"     </li>",
"     <li>",
"      Inguinal hernia &mdash; Inguinal hernias occur in up to 82 percent of boys and 11 percent of girls with bladder exstrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/24/24966/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Genitalia &mdash; Although genitalia defects occur in both sexes, defects are generally more severe and complex in affected males.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Males &mdash; In affected males, clinical features include epispadias with the urethral opening along the dorsal (top) surface aspect of the penis, dorsal (upward) curvature with absent dorsal foreskin, and an open prostate gland, which does not encircle the urethra but lies posterior to it (",
"      <a class=\"graphic graphic_figure graphicRef53828 \" href=\"UTD.htm?22/46/23267\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef59654 \" href=\"UTD.htm?27/26/28079\">",
"       picture 2",
"      </a>",
"      ). The penis is shortened because of marked deficiency of anterior corpora cavernosa tissue and the diastasis of the symphysis pubis (",
"      <a class=\"graphic graphic_figure graphicRef75574 \" href=\"UTD.htm?36/45/37584\">",
"       figure 2",
"      </a>",
"      ). Magnetic resonance imaging demonstrates shorter anterior corporal (erectile",
"      <span class=\"nowrap\">",
"       body/tissue)",
"      </span>",
"      length in both neonatal and adult male patients with bladder exstrophy compared to normal controls [",
"      <a class=\"abstract\" href=\"UTD.htm?24/24/24966/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Females &mdash; Affected females have epispadias with a bifid clitoris and small, laterally displaced labia minora (",
"      <a class=\"graphic graphic_picture graphicRef73750 \" href=\"UTD.htm?16/33/16914\">",
"       picture 1",
"      </a>",
"      ).The vagina, which is of otherwise normal caliber is shortened compared to normals. In the sexually active mature female, vaginal dilation may occasionally be required to allow satisfactory sexual intercourse. The fallopian tubes and ovaries are generally normal. Female patients may be predisposed to the development of uterine prolapse, which may require corrective surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?24/24/24966/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are also rare variants of the classic bladder exstrophy that include the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Superior vesical fissure &mdash; These patients have the typical muscular and skeletal defects of classic bladder exstrophy, but only the upper (cephalad) portion of the bladder is affected. The urethra may be intact.",
"     </li>",
"     <li>",
"      Pseudoexstropy &mdash; These patients have the typical muscular and skeletal defects of classic bladder exstrophy but do not have any urinary tract abnormality (ie, intact normal urinary system).",
"     </li>",
"     <li>",
"      Duplicate exstrophy &mdash; These patients have a duplicated lower urinary tract, which includes one closed system and one open system with an exposed bladder and urethra.",
"     </li>",
"     <li>",
"      Covered exstrophy &mdash; These patients have the typical muscular and skeletal defects of classic bladder exstrophy with only a skin covering over the bladder and urethra.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often the diagnosis of bladder exstrophy is made by prenatal ultrasound and, in some cases, may be confirmed by magnetic resonance imaging (MRI). In the event that a prenatal diagnosis is not made, the diagnosis should be clinically apparent and recognizable at birth in the delivery room. In our center, 43 percent of patients who presented from 1996 to 2004 were diagnosed prenatally [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24966/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prenatal ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a review of 40 prenatal US examinations performed in 25 pregnancies in which the offspring had classic bladder exstrophy, the following findings were consistent with the prenatal diagnosis of bladder exstrophy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64600 \" href=\"UTD.htm?40/61/41939\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24966/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Absence of bladder filling",
"     </li>",
"     <li>",
"      Low-set umbilicus",
"     </li>",
"     <li>",
"      Pubic bone diastasis",
"     </li>",
"     <li>",
"      Diminutive genitalia",
"     </li>",
"     <li>",
"      Lower abdominal mass that increases in size as the pregnancy progresses and as the intra-abdominal viscera increase in size.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Delivery room",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a prenatal diagnosis is not made, the diagnosis of bladder exstrophy should be clinically recognizable at delivery. A careful physical examination will differentiate bladder exstrophy from other congenital anomalies that involve abdominal wall defects, such as omphalocele, gastroschisis, and cloacal exstrophy.",
"   </p>",
"   <p>",
"    Important features of the initial physical examination include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Size of the bladder template &mdash; The size of the bladder template may affect the timing of surgical closure. Patients with a small bladder plate may have delayed reconstruction to allow further growth of the bladder to facilitate successful bladder closure.",
"     </li>",
"     <li>",
"      Position of the testes &mdash; As for any newborn male infant, the examination should identify the position of the testes to exclude cryptorchidism. In boys with bladder exstrophy, the testes may appear to be undescended in their course from the widened pubic tubercles to the flat, wide scrotum. However, most males with bladder exstrophy do not have cryptorchidism and do not require orchiopexy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17098?source=see_link\">",
"       \"Undescended testes (cryptorchidism) in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Presence of an inguinal hernia &mdash; If present, an inguinal hernia may be repaired at the time of surgical closure of the bladder.",
"     </li>",
"     <li>",
"      Periumbilical anatomy (eg, presence of omphalocele) &mdash; The presence of an omphalocele suggests a diagnosis of cloacal exstrophy. However, omphalocele (protruding, covered intraabdominal organs) may occasionally be associated with bladder exstrophy.",
"     </li>",
"     <li>",
"      Position of the anus &mdash; The anus is usually displaced anteriorly, which may have important clinical implications for urinary and fecal continence, pelvic organ prolapse, and surgical reconstruction. However, surgical revision of the anus is generally uncommon.",
"     </li>",
"     <li>",
"      Degree of pubic symphysis diastasis and malleability of the pelvis &mdash; The need for pelvic osteotomy at the time of bladder closure is dependent upon the severity of these two features. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11849?source=see_link&amp;anchor=H6#H6\">",
"       \"Surgical management and postoperative outcome of children with bladder exstrophy\", section on 'Neonatal iliac osteotomy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Prenatal care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the prenatal diagnosis of bladder exstrophy, prenatal care includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Education and counseling of the parents &mdash; This includes reviewing the diagnosis of bladder exstrophy and its implications, touring the neonatal intensive care unit, meeting the pediatric urologic care team, and allowing the expectant parent(s) the opportunity to interact with other families with a child with bladder exstrophy.",
"     </li>",
"     <li>",
"      Preparation for delivery &mdash; In many tertiary centers, one option for planning initial surgical management is an induced vaginal delivery that is scheduled in late gestation with coordination with an on-site pediatric urology service. This approach facilitates bladder closure within 72 hours of life. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11849?source=see_link&amp;anchor=H2#H2\">",
"       \"Surgical management and postoperative outcome of children with bladder exstrophy\", section on 'Surgical approaches'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Delivery room and nursery care",
"    </span>",
"    &nbsp;&mdash;&nbsp;After delivery of an infant with bladder exstrophy, it is important to limit trauma to the mucosa of the exposed open bladder as outlined by the following measures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After initial routine plastic clamp occlusion of the umbilical cord at delivery, the clamp is exchanged for soft cloth umbilical \"tape\" or silk ligature to limit trauma to the bladder.",
"     </li>",
"     <li>",
"      The bladder is covered with a nonadherent film of plastic wrap, such as a transparent adhesive dressing. This wrap provides protection by covering without sticking to the bladder and urethra, and adhering to the surrounding intact skin. It allows egress of urine and avoids irritation to the exposed bladder and urethra from abrasive diapers.",
"     </li>",
"     <li>",
"      The bladder may be irrigated intermittently with sterile saline during diaper changes, although this is not absolutely necessary.",
"     </li>",
"     <li>",
"      For a newborn who presents at delivery without a prior antenatal diagnosis, pediatric urology, orthopedics, anesthesia, and social services should be consulted during the newborn period.",
"     </li>",
"     <li>",
"      Broad-spectrum antibiotics are generally not necessary prior to initial reconstructive surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Preoperative evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preoperative evaluation includes blood tests and imaging studies.",
"   </p>",
"   <p>",
"    The laboratory evaluation includes a complete blood count, serum electrolytes, and renal function tests. Blood urea nitrogen and creatinine at birth are reflective of maternal renal functions, and subsequent tests are useful in determining whether or not there is any renal impairment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27114?source=see_link&amp;anchor=H13#H13\">",
"     \"Acute kidney injury (acute renal failure) in the newborn\", section on 'Serum creatinine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Imaging studies performed within the first two days of life prior to complete primary repair include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal ultrasound to screen for any congenital anomaly of the kidney or urinary tract (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=see_link\">",
"       \"Overview of congenital anomalies of the kidney and urinary tract (CAKUT)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Abdominal plain film to measure the degree of pubic diastasis",
"     </li>",
"     <li>",
"      Possible pelvic magnetic resonance imaging to assess the bony and soft tissue anatomy of the pelvis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/24/24966/abstract/17\">",
"       17",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11849?source=see_link\">",
"       \"Surgical management and postoperative outcome of children with bladder exstrophy\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder exstrophy is a complex congenital anomaly within the exstrophy-epispadias complex, a spectrum that involves the musculoskeletal system and the urinary, genital, and intestinal tracts. The other two conditions within this complex are epispadias and cloacal exstrophy. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Exstrophy-epispadias complex'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pathogenesis of bladder exstrophy appears to be due to an embryological defect in abdominal wall development due to the in utero rupture of an overdeveloped cloacal membrane that results in herniation of lower abdominal components, including the open, exposed urinary bladder, onto the lower abdominal wall surface. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence of bladder exstrophy is about 1 per 30,000 to 50,000 live births. It occurs more frequently in males, firstborn children, and in white infants. The incidence increases in offspring of affected individuals to a rate of 1 in 70 live births. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical features of classic bladder exstrophy are an open bladder and exposure of the urethra at the surface of the lower abdomen, low set umbilicus, diastasis of the symphysis pubis, anteriorly displaced anus, inguinal hernia, and genitalia defects, which are generally more severe and complex in male than female patients (",
"      <a class=\"graphic graphic_picture graphicRef73750 \" href=\"UTD.htm?16/33/16914\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef53828 \" href=\"UTD.htm?22/46/23267\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef59654 \" href=\"UTD.htm?27/26/28079\">",
"       picture 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef58943 \" href=\"UTD.htm?19/15/19696\">",
"       picture 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef55640 \" href=\"UTD.htm?19/50/20257\">",
"       image 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of bladder exstrophy is often made by prenatal ultrasound (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef64600 \" href=\"UTD.htm?40/61/41939\">",
"       image 2",
"      </a>",
"      ) or, if a prenatal diagnosis is not made, the diagnosis is apparent immediately at birth. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial management for bladder exstrophy includes the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Prenatal care &mdash; When the diagnosis is made prenatally, prenatal care may include parental education and counseling, and scheduled delivery in late gestation at a tertiary center with an available on-site pediatric urology service, which can coordinate perioperative evaluation and surgical repair following the scheduled delivery. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Prenatal care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After delivery, it is important to limit trauma to the mucosa of the exposed open bladder and urethra. Suggested measures include replacement of the plastic clamp routinely used to occlude the umbilical cord with a soft silk ligature or umbilical tape and covering the bladder with soft plastic wrap. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Delivery room and nursery care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the neonate who was not diagnosed prenatally, pediatric urology, orthopedics, anesthesia, and social services should be consulted in the newborn period.",
"     </li>",
"     <li>",
"      Perioperative evaluation includes a complete physical evaluation, laboratory testing (ie, complete blood count and serum electrolytes), and imaging (ie, renal ultrasound, abdominal plain film, and possibly, pelvic magnetic resonance imaging). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Delivery room'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Preoperative evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The surgical and postoperative management of bladder exstrophy is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11849?source=see_link\">",
"       \"Surgical management and postoperative outcome of children with bladder exstrophy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Richard Silver, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24966/abstract/1\">",
"      Reutter H, Boyadjiev SA, Gambhir L, et al. Phenotype severity in the bladder exstrophy-epispadias complex: analysis of genetic and nongenetic contributing factors in 441 families from North America and Europe. J Pediatr 2011; 159:825.",
"     </a>",
"    </li>",
"    <li>",
"     Marshall VF, Muecke EC. Congenital abnormalities of the bladder. In: Handbuch de Urologie, Springer-Verlag, New York 1968. p.165.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24966/abstract/3\">",
"      Epidemiology of bladder exstrophy and epispadias: a communication from the International Clearinghouse for Birth Defects Monitoring Systems. Teratology 1987; 36:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24966/abstract/4\">",
"      Jayachandran D, Bythell M, Platt MW, Rankin J. Register based study of bladder exstrophy-epispadias complex: prevalence, associated anomalies, prenatal diagnosis and survival. J Urol 2011; 186:2056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24966/abstract/5\">",
"      Shapiro E, Lepor H, Jeffs RD. The inheritance of the exstrophy-epispadias complex. J Urol 1984; 132:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24966/abstract/6\">",
"      Nelson CP, Dunn RL, Wei JT. Contemporary epidemiology of bladder exstrophy in the United States. J Urol 2005; 173:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24966/abstract/7\">",
"      Messelink EJ, Aronson DC, Knuist M, et al. Four cases of bladder exstrophy in two families. J Med Genet 1994; 31:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24966/abstract/8\">",
"      Sponseller PD, Bisson LJ, Gearhart JP, et al. The anatomy of the pelvis in the exstrophy complex. J Bone Joint Surg Am 1995; 77:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24966/abstract/9\">",
"      Stec AA, Pannu HK, Tadros YE, et al. Evaluation of the bony pelvis in classic bladder exstrophy by using 3D-CT: further insights. Urology 2001; 58:1030.",
"     </a>",
"    </li>",
"    <li>",
"     Gearhart J. Exstrophy, Epispadias, and Other Bladder Anomalies, 8th, WB Saunders, Philadelphia 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24966/abstract/11\">",
"      Connolly JA, Peppas DS, Jeffs RD, Gearhart JP. Prevalence and repair of inguinal hernias in children with bladder exstrophy. J Urol 1995; 154:1900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24966/abstract/12\">",
"      Silver RI, Yang A, Ben-Chaim J, et al. Penile length in adulthood after exstrophy reconstruction. J Urol 1997; 157:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24966/abstract/13\">",
"      Halachmi S, Farhat W, Konen O, et al. Pelvic floor magnetic resonance imaging after neonatal single stage reconstruction in male patients with classic bladder exstrophy. J Urol 2003; 170:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24966/abstract/14\">",
"      Mathews RI, Gan M, Gearhart JP. Urogynaecological and obstetric issues in women with the exstrophy-epispadias complex. BJU Int 2003; 91:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24966/abstract/15\">",
"      Borer JG, Gargollo PC, Hendren WH, et al. Early outcome following complete primary repair of bladder exstrophy in the newborn. J Urol 2005; 174:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24966/abstract/16\">",
"      Gearhart JP, Ben-Chaim J, Jeffs RD, Sanders RC. Criteria for the prenatal diagnosis of classic bladder exstrophy. Obstet Gynecol 1995; 85:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24966/abstract/17\">",
"      Gargollo PC, Borer JG, Retik AB, et al. Magnetic resonance imaging of pelvic musculoskeletal and genitourinary anatomy in patients before and after complete primary repair of bladder exstrophy. J Urol 2005; 174:1559.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6576 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-D1AB04EF24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_24_24966=[""].join("\n");
var outline_f24_24_24966=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EXSTROPHY-EPISPADIAS COMPLEX",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Variants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prenatal ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Delivery room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Prenatal care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Delivery room and nursery care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Preoperative evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6576\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6576|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/50/20257\" title=\"diagnostic image 1\">",
"      Diastasis symphysis pubis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/61/41939\" title=\"diagnostic image 2\">",
"      Bladder exstrophy prenatal ultrasound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6576|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/46/23267\" title=\"figure 1\">",
"      Bladder exstrophy male",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/45/37584\" title=\"figure 2\">",
"      Penile anatomy in exstrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6576|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/33/16914\" title=\"picture 1\">",
"      Bladder exstrophy female",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/26/28079\" title=\"picture 2\">",
"      Exstrophy small bladder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/15/19696\" title=\"picture 3\">",
"      Bladder exstrophy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27114?source=related_link\">",
"      Acute kidney injury (acute renal failure) in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6488?source=related_link\">",
"      Obstetrical and neonatal management of body stalk anomalies and cloacal abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=related_link\">",
"      Overview of congenital anomalies of the kidney and urinary tract (CAKUT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11849?source=related_link\">",
"      Surgical management and postoperative outcome of children with bladder exstrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17098?source=related_link\">",
"      Undescended testes (cryptorchidism) in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_24_24967="Verrucous carcinoma";
var content_f24_24_24967=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F57350%7EDERM%2F55834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F57350%7EDERM%2F55834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Verrucous carcinoma of the oral cavity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Verrucous carcinoma of the oral cavity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vaibhav Parekh, MD MBA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Verrucous carcinoma of the oral cavity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Verrucous carcinoma of the oral cavity (oral florid papillomatosis).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_24_24967=[""].join("\n");
var outline_f24_24_24967=null;
var title_f24_24_24968="Gastrointestinal manifestations of vasculitis";
var content_f24_24_24968=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gastrointestinal manifestations of vasculitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/24/24968/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/24/24968/contributors\">",
"     Michael D Apstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/24/24968/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/24/24968/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/24/24968/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/24/24968/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/24/24968/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasculitis involving the gastrointestinal tract is usually part of a systemic process, although the signs and symptoms may initially be limited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link\">",
"     \"Classification of and approach to the vasculitides in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will cover the clinical manifestations and approach to the diagnosis of gastrointestinal vasculitis; the individual disorders, such as polyarteritis nodosa (PAN) and systemic lupus erythematosus (SLE), are discussed in detail elsewhere, as are systemic vasculitides without prominent gastrointestinal manifestations, such as granulomatosis with polyangiitis (Wegener&rsquo;s) and mixed cryoglobulinemia. The latter disorder is of interest to gastroenterologists because it usually represents an extrahepatic manifestation of hepatitis C virus infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5928?source=see_link\">",
"     \"Gastrointestinal manifestations of systemic lupus erythematosus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signs and symptoms of systemic vasculitis involving the gastrointestinal tract result from mesenteric ischemia. In contrast to patients with chronic mesenteric ischemia due to a low flow state, who usually give a history of chronic abdominal pain, patients with vasculitis involving the gastrointestinal tract may present with acute abdominal pain. Similar to patients with chronic mesenteric ischemia, these patients frequently have pain that is out of proportion with findings on abdominal exam before intestinal infarction occurs. Clinicians should consider gastrointestinal vasculitis in this setting in the absence of a source of embolization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44377?source=see_link\">",
"     \"Acute mesenteric ischemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33206?source=see_link\">",
"     \"Chronic mesenteric ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In three series with a total of 351 patients, approximately one-third had gastrointestinal manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In one large series of patients with PAN or Churg-Strauss syndrome, for example, the following frequency of gastrointestinal symptoms and findings was noted [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abdominal pain &mdash; 25 percent",
"     </li>",
"     <li>",
"      Gastrointestinal bleeding &mdash; 7 percent",
"     </li>",
"     <li>",
"      Peritonitis &mdash; 4 percent",
"     </li>",
"     <li>",
"      Intestinal infarction, pancreatitis, and duodenal ulcer &mdash; 2 percent each",
"     </li>",
"     <li>",
"      Cholecystitis &mdash; 1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients with systemic vasculitis and documented gastrointestinal involvement, the prevalence of symptoms is much greater. As an example, in one study of 62 such patients, the following symptoms were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abdominal pain &mdash; 97 percent",
"     </li>",
"     <li>",
"      Nausea or vomiting &mdash; 34 percent",
"     </li>",
"     <li>",
"      Diarrhea &mdash; 27 percent",
"     </li>",
"     <li>",
"      Hematochezia or melena &mdash; 16 percent",
"     </li>",
"     <li>",
"      Hematemesis &mdash; 6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ischemic hepatitis, gastritis, esophagitis, pancreatitis, and appendicitis also can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with gastrointestinal vasculitis can also have symptoms of chronic mesenteric ischemia, such as abdominal pain after eating (&ldquo;intestinal angina&rdquo;), weight loss, nausea, vomiting, and diarrhea. These patients can also present acutely with small bowel obstruction secondary to strictures, resembling Crohn&rsquo;s disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/5\">",
"     5",
"    </a>",
"    ] or intussusception, or with massive gastrointestinal bleeding secondary to aneurysm formation. Bowel obstruction secondary to an ischemic stricture has been reported to precede the systemic manifestation in Churg-Strauss syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/6\">",
"     6",
"    </a>",
"    ]. Although bowel infarction, perforation, and peritonitis are rare complications of chronic intestinal ischemia due to vasculitis, they can occur during acute ischemic episodes, and the clinician must be vigilant because the patient may need surgery to prevent or treat them. In addition to mesenteric ischemia, systemic vasculitis can also cause ischemic hepatitis, pancreatitis, cholecystitis, and, less commonly, gastritis or esophagitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33206?source=see_link\">",
"     \"Chronic mesenteric ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SPECIFIC DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the ischemic symptoms are similar regardless of the systemic vasculitis, several specific syndromes deserve mention. Polyarteritis nodosa is a particular problem, because of the larger size of the vessels involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Polyarteritis nodosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyarteritis nodosa (PAN) affects small- and medium-sized arteries (",
"    <a class=\"graphic graphic_picture graphicRef74893 \" href=\"UTD.htm?8/49/8985\">",
"     picture 1",
"    </a>",
"    ) and can cause a variety of gastrointestinal symptoms as noted above [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    About 7 percent of patients with PAN have it in association with hepatitis B virus (HBV) infection, but less than 1 percent of patients with HBV develop polyarteritis. Most PAN develops within 12 months of the initial infection and is thought to be the result of deposition of viral antigen-antibody complexes in vessel walls. The hepatitis is usually silent at the onset of PAN with a mild increase in serum transaminases in only about one-half of patients. PAN associated with HBV has a greater likelihood of gastrointestinal involvement than PAN that is not associated with HBV. The one-year survival for patients with HBV-associated PAN is lower because of an increased incidence of gastrointestinal bleeding and perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations and natural history of hepatitis B virus infection\", section on 'Extrahepatic manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gastrointestinal involvement occurs in 14 to 65 percent of patients with PAN, with the gallbladder and small bowel as the most frequent sites of involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/7\">",
"     7",
"    </a>",
"    ]. The more severe manifestations include intestinal infarction or perforation, pneumatosis intestinalis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/8\">",
"     8",
"    </a>",
"    ], pseudomembranous colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/9\">",
"     9",
"    </a>",
"    ], and cholecystitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/10\">",
"     10",
"    </a>",
"    ]. In one series of 16 patients hospitalized with severe PAN, five developed an abdominal crisis related to the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/11\">",
"     11",
"    </a>",
"    ]. At laparotomy, all five had gross evidence of mesenteric arteritis with infarcted bowel and intestinal perforation. All five patients died despite surgery and medical therapy. In another series of 165 patients with PAN or Churg-Strauss syndrome, 31 percent of deaths during follow-up were attributable to gastrointestinal disease (gastrointestinal bleeding or peritonitis in 11 and pancreatitis in two) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/1\">",
"     1",
"    </a>",
"    ]. Concomitant care with a surgeon is important to reduce morbidity and mortality from perforation. Liver involvement is also common but most often is not clinically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of PAN with glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    has led to a dramatic improvement in patient survival and usually in relief of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients with PAN related to HBV infection or hairy cell leukemia may involve treatment of these underlying disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28119?source=see_link\">",
"     \"Treatment and prognosis of polyarteritis nodosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The tendency of PAN to involve large vessels has an important long-term implication. Some patients with PAN have gastrointestinal symptoms and other manifestations at a time when the disease is clinically inactive due to effective immunosuppressive therapy. In this setting, healing of inflamed vessels has led to progressive narrowing of the vascular lumens and true arteriosclerosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Churg-Strauss syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Churg-Strauss syndrome (also called allergic granulomatosis and angiitis) is a multisystem disease similar to PAN except for the characteristic triad of allergic rhinitis, asthma, and prominent peripheral blood eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=see_link\">",
"     \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Henoch-Sch&ouml;nlein purpura (HSP) (IgA vasculitis [IgAV]) is a small-vessel vasculitis that typically occurs in children, although all ages can be affected. Patients classically exhibit lower extremity purpura, arthritis, and hematuria. The gastrointestinal tract is affected in up to 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gastrointestinal symptoms include colicky abdominal pain, nausea, vomiting, diarrhea, constipation, and occult or overt intestinal bleeding. The course can wax and wane over several weeks and often resolves spontaneously.",
"   </p>",
"   <p>",
"    The diagnosis of HSP is often suspected clinically. Confirmation of the diagnosis requires evidence of tissue deposition in the skin or kidney of immunoglobulin A (IgA) by immunofluorescence microscopy (",
"    <a class=\"graphic graphic_picture graphicRef69895 \" href=\"UTD.htm?23/2/23599\">",
"     picture 2",
"    </a>",
"    ). Biopsy of the skin lesions reveals inflammation of the small blood vessels and leukocytoclastic vasculitis, which is most prominent in the postcapillary venules (",
"    <a class=\"graphic graphic_picture graphicRef52548 graphicRef66296 \" href=\"UTD.htm?7/58/8106\">",
"     picture 3A-B",
"    </a>",
"    ). This finding is relatively nonspecific (also being found in other forms of hypersensitivity vasculitis) unless accompanied by vascular IgA deposition which can, in some cases, also be seen in areas of seemingly uninvolved skin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of treatment is controversial. The overall outcome is good in most patients; as an example, complete recovery occurred in 94 percent of children and in 89 percent of adults in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/17\">",
"     17",
"    </a>",
"    ]. All of the manifestations of active HSP usually resolve spontaneously, although recurrent episodes of purpura and glomerulonephritis may be seen. Responses to glucocorticoids, immunosuppressive drugs, and plasma exchange have been reported anecdotally in patients with severe disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Systemic lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vasculitis associated with systemic lupus erythematosus (SLE) involves small- and medium-sized vessels and involves the gastrointestinal tract in up to 50 percent of patients. Lower abdominal pain secondary to mesenteric vasculitis is generally an insidious symptom that may be intermittent for months prior to the development of an acute abdomen with nausea, vomiting, diarrhea, GI bleeding, and fever [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/11\">",
"     11",
"    </a>",
"    ]. Risk factors for the development of mesenteric vasculitis include peripheral vasculitis and central nervous system lupus. Patients with an acute presentation may also have mesenteric thrombosis and infarction, often in association with antiphospholipid antibodies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5928?source=see_link\">",
"     \"Gastrointestinal manifestations of systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mesenteric vasculitis is a potentially life-threatening disorder. In addition to the possible development of necrotic segments of bowel, patients may suffer septic complications and bowel perforation. In an older series published in 1982, 15 of 140 patients with SLE who required hospital admission developed a disease-related abdominal event [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/11\">",
"     11",
"    </a>",
"    ]. Eleven of the 15 underwent exploratory laparotomy, six had intestinal perforations (five colonic and one in the small intestine), and three had bowel that was in imminent danger of perforating. These changes were due to intestinal vasculitis; only two of the patients who underwent surgery had polyserositis without evidence of vasculitis. Four patients responded to glucocorticoids alone while surgery was being considered. Therapy of severe SLE is more aggressive and typically consists of intravenous pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    and pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5928?source=see_link\">",
"     \"Gastrointestinal manifestations of systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of patients in the preceding study had a prodrome characterized by the insidious onset of intermittent lower quadrant cramping and abdominal pain, which were present for an average of 34 days prior to hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/11\">",
"     11",
"    </a>",
"    ]. The presence of these symptoms in patients with SLE should raise suspicion of possible mesenteric vasculitis, thereby permitting early diagnosis and treatment. In the absence of therapy, symptoms tend to progress. In the above series, anorexia, nausea, and vomiting were common at presentation (in addition to abdominal pain), and five patients (33 percent) had diarrhea and melena.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Antiphospholipid syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antiphospholipid syndrome (APS) can occur in patients with SLE or as an isolated disorder. APS is not a vasculitis. However, when abdominal symptoms occur in a patient with APS and SLE, the patient may erroneously be considered to have a mesenteric vasculitis. This distinction may be of critical importance because treatment of APS consists of anticoagulation, not immunosuppressive therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=see_link\">",
"     \"Treatment of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    APS represents a hypercoagulable state which can be associated with a variety of clinical features. including arterial and venous thrombosis, livedo reticularis, and spontaneous abortions. Gastrointestinal manifestations of APS are due to ischemia involving the esophagus, stomach, duodenum, jejunoileum, or colon, resulting in gastrointestinal bleeding, abdominal pain, an acute abdomen, esophageal necrosis with perforation, or giant gastric ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/18-22\">",
"     18-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of APS is made by consideration of both the clinical history and the laboratory findings, particularly in patients with SLE. Criteria have been proposed that require at least one of the following clinical findings",
"    <strong>",
"     and",
"    </strong>",
"    at least one of the following laboratory test results which must be positive on at least two occasions more than three months apart [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clinical &mdash; Recurrent venous or arterial thrombosis, recurrent fetal loss, persistent thrombocytopenia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      livedo reticularis",
"     </li>",
"     <li>",
"      Laboratory &mdash; IgG or IgM anticardiolipin antibody, anti-&szlig;2-glycoprotein I antibody,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lupus anticoagulant activity",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10734207\">",
"    <span class=\"h2\">",
"     Rheumatoid vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;When it occurs, rheumatoid vasculitis often presents 10 to 15 years after the onset of rheumatoid arthritis (RA). Although autopsy studies suggest it is common, occurring in 25 percent of patients, less than 1 percent of patients with RA develop clinical signs of vasculitis. Ten to 38 percent of these patients will have gastrointestinal manifestations of the vasculitis, usually mesenteric ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rheumatoid vasculitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Beh&ccedil;et's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beh&ccedil;et&rsquo;s disease is a necrotizing vasculitis of unknown etiology primarily affecting young adult males. It is characterized by oral and genital ulcerations, uveitis, and skin lesions. Gastrointestinal ulcerations occur in some patients with Beh&ccedil;et&rsquo;s disease. Discrete ulcerations are most often seen in the terminal ileum, cecum, ascending colon, and esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. Acute pancreatitis has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal management of Beh&ccedil;et&rsquo;s disease is uncertain, since the disease is rare and since symptoms tend to wax and wane. The mucocutaneous lesions can be treated with topical or intralesional corticosteroids or with systemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    , or glucocorticoids. Systemic disease is typically treated with glucocorticoids and immunosuppressive drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33498?source=see_link\">",
"     \"Treatment of Beh&ccedil;et&rsquo;s disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Inflammatory bowel disease associated vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasculitis is often considered in the differential diagnosis of inflammatory bowel disease (IBD), especially Crohn&rsquo;s disease. Indeed, some investigators have suggested that vasculitis induced by measles virus infection may be a cause of Crohn&rsquo;s disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/30\">",
"     30",
"    </a>",
"    ]. Furthermore, IBD may rarely be associated vasculitis involving the skin or retina [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41350?source=see_link\">",
"     \"Skin and eye manifestations of inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Takayasu arteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Takayasu arteritis is a chronic vasculitis of unknown etiology that predominantly affects the aorta and its primary branches [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Women are affected in 80 to 90 percent of cases, with an age of onset that is usually between 10 and 40 years; the prevalence is greatest in Asians. Although not a major feature, mesenteric ischemia can occur, leading to abdominal pain, to diarrhea, and to gastrointestinal hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/19/13624?source=see_link\">",
"     \"Clinical features and diagnosis of Takayasu arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Jejunal vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are at least two poorly understood syndromes involving vasculitis seemingly confined to the small bowel. Segmental vasculitis involving the small bowel, manifested by protein-losing enteropathy and abdominal pain, has been reported following bone marrow transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/34\">",
"     34",
"    </a>",
"    ]. Chronic ulcerative nongranulomatous jejunitis, characterized by chronic diarrhea, multiple small bowel ulcerations, and villous atrophy, or cryptogenic multifocal ulcerous stenosing enteritis (CMUSE), characterized by bouts of intestinal obstruction, may be due to a vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Drug-induced vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/9/5271?source=see_link\">",
"     propylthiouracil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    , have been associated with intestinal vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EVALUATION OF THE PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with gastrointestinal manifestations of a systemic vasculitis have other symptoms suggesting the diagnosis of the underlying disease, and some will have already been diagnosed. The methods of diagnosing the different forms of vasculitis are described separately on the appropriate topic reviews. Although there is much overlap among these disorders, classification criteria have been suggested. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link\">",
"     \"Classification of and approach to the vasculitides in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several serologic markers, such as antinuclear antibodies (ANA) and antineutrophil cytoplasmic antibodies (ANCA), are associated with specific types of vasculitis or SLE, but tissue biopsy is often required to establish the diagnosis. A potential source of confusion with ANCA in patients with gastrointestinal complaints is that positive testing for perinuclear ANCA (P-ANCA) is also associated with a variety of gastrointestinal diseases in the absence of vasculitis, such as inflammatory bowel disease (particularly ulcerative colitis) and autoimmune liver diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. These antibodies are usually not directed against myeloperoxidase, the antigen typically involved in vasculitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The erythrocyte sedimentation rate (ESR) is almost always elevated in patients with active vasculitis. However, this sensitive marker is also nonspecific. On the other hand, a normal ESR virtually excludes vasculitis, although exceptions do occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The serum lactate level is helpful in evaluating patients with suspected mesenteric ischemia, although it is not specific and although a normal value does not exclude this condition. An elevated serum lactate provides evidence of an underlying disease process requiring further evaluation when the diagnosis is unclear or when other clinical signs of mesenteric ischemia are absent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual imaging studies, computerized tomographic angiography or magnetic resonance angiography, are useful for patients with suspected vasculitis-induced mesenteric ischemia in identifying intestinal mucosal or submucosal abnormalities but not vessel involvement, except for those with polyarteritis nodosa or Takayasu arteritis, because of the small size of the vessels involved [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Angiography may be useful in diagnosing small- and medium-vessel vasculitis, such as PAN (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65987 \" href=\"UTD.htm?35/54/36705\">",
"     image 1",
"    </a>",
"    ). Nuclear medicine scanning using white blood cell markers such as Indium-111 may localize bowel inflammation in vasculitis, but its clinical utility is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopy should be performed with GREAT CAUTION in the evaluation of a patient with suspected GI involvement from an acute flare of vasculitis because of the elevated risk of perforation in the setting of an edematous, ischemic bowel. Video capsule endoscopy may be an option [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24968/abstract/43\">",
"     43",
"    </a>",
"    ]. Biopsy confirmation of vasculitis, if the diagnosis has not been established, can almost always be made from more easily accessible sites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two components to the treatment of intestinal vasculitis. The first is treatment of the underlying disease, usually with immunosuppressive agents. (See appropriate topic reviews.) The second component of therapy is aimed at the gastrointestinal symptoms. For patients with mesenteric ischemia, control of the vasculitis should lead to symptom resolution. An exception, as noted above, is that ischemic symptoms can occur late and in the absence of active disease in patients with healed PAN in whom scarring has led to progressive attenuation of the vascular lumen. Surgical intervention is warranted in patients with mesenteric infarction or with intestinal perforation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10733896\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The signs and symptoms of systemic vasculitis involving the gastrointestinal (GI) tract result from mesenteric ischemia. Most patients experience abdominal pain, which may be acute or chronic; the latter presentation is also characteristic of chronic mesenteric ischemia due to a low flow state and may include abdominal pain after eating and weight loss, in addition to nausea, vomiting, and diarrhea. Nausea, vomiting, diarrhea, and hematochezia or melena occur in one-third to one-sixth of patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The abdominal pain is frequently out of proportion with findings on examination before intestinal infarction occurs, and such pain should raise suspicion of GI vasculitis in the absence of a source of embolization. Strictures, intussusception, and bleeding can occur. Acute ischemia can result in bowel infarction, perforation, and peritonitis; they are rare in patients with chronic intestinal ischemia due to vasculitis. Ischemic hepatitis, pancreatitis, cholecystitis, esophagitis, gastritis, and appendicitis may also be seen. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Polyarteritis nodosa (PAN) affects small- and medium-sized arteries and can cause a variety of GI symptoms. GI involvement is common, with the gallbladder and small bowel as the most frequent sites affected. Patients with concurrent hepatitis B have an increased likelihood of GI involvement, including GI bleeding and perforation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Polyarteritis nodosa'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Symptoms'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=see_link\">",
"       \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      GI involvement occurs in up to 50 percent of patients with Henoch-Sch&ouml;nlein purpura (IgA vasculitis). Symptoms include colicky abdominal pain, nausea, vomiting, diarrhea, constipation, and occult or overt intestinal bleeding. The course can wax and wane over several weeks and often resolves spontaneously. The efficacy of treatment is controversial. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Henoch-Sch&ouml;nlein purpura (IgA vasculitis)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The vasculitis associated with systemic lupus erythematosus (SLE) involves small- and medium-sized vessels and involves the gastrointestinal tract in up to 50 percent of patients. Lower abdominal pain and cramping secondary to mesenteric vasculitis are generally insidious and may be intermittent for months prior to the development of an acute abdomen with nausea, vomiting, diarrhea, GI bleeding, and fever. Patients with SLE and an acute presentation of abdominal pain may also have mesenteric thrombosis and infarction, often in association with antiphospholipid antibodies, which should be distinguished from vasculitis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Systemic lupus erythematosus'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Antiphospholipid syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other forms of vasculitis with risk of significant GI involvement include Churg-Strauss syndrome, rheumatoid vasculitis, Beh&ccedil;et&rsquo;s disease, inflammatory bowel disease-associated vasculitis, Takayasu arteritis, jejunal vasculitis, and drug-induced vasculitis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Churg-Strauss syndrome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10734207\">",
"       'Rheumatoid vasculitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Beh&ccedil;et's disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Inflammatory bowel disease associated vasculitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Takayasu arteritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Jejunal vasculitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Drug-induced vasculitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with GI manifestations of a systemic vasculitis have other symptoms suggesting the diagnosis of the underlying disease and, some will have already been diagnosed. The erythrocyte sedimentation rate (ESR) is almost always elevated in patients with active vasculitis but is nonspecific; a normal ESR usually virtually excludes vasculitis. Imaging can identify abnormal mucosa or submucosa but not small-vessel involvement. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Evaluation of the patient'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endoscopy should be performed with great caution, if required, in the evaluation of a patient with suspected GI involvement from an acute flare of vasculitis because of the elevated risk of perforation in the setting of an edematous, ischemic bowel. Biopsy confirmation of vasculitis, if the diagnosis has not been established, can almost always be made from more easily accessible sites. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Endoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The two principle components of the treatment of intestinal vasculitis are treatment of the underlying disease, usually with immunosuppressive agents, and therapy aimed at the GI symptoms. For most patients with mesenteric ischemia, timely control of the vasculitis should lead to symptom resolution. Surgical intervention is warranted in patients with mesenteric infarction or with intestinal perforation. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/1\">",
"      Guillevin L, Le Thi Huong Du, Godeau P, et al. Clinical findings and prognosis of polyarteritis nodosa and Churg-Strauss angiitis: a study in 165 patients. Br J Rheumatol 1988; 27:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/2\">",
"      Scott DG, Bacon PA, Elliott PJ, et al. Systemic vasculitis in a district general hospital 1972-1980: clinical and laboratory features, classification and prognosis of 80 cases. Q J Med 1982; 51:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/3\">",
"      Lopez LR, Schocket AL, Stanford RE, et al. Gastrointestinal involvement in leukocytoclastic vasculitis and polyarteritis nodosa. J Rheumatol 1980; 7:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/4\">",
"      Pagnoux C, Mahr A, Cohen P, Guillevin L. Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine (Baltimore) 2005; 84:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/5\">",
"      Kuehne SE, Gauvin GP, Shortsleeve MJ. Small bowel stricture caused by rheumatoid vasculitis. Radiology 1992; 184:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/6\">",
"      Vaglio A, Corradi D, Ronda N, et al. Large bowel obstruction heralding Churg-Strauss syndrome. Am J Gastroenterol 2004; 99:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/7\">",
"      Ebert EC, Hagspiel KD, Nagar M, Schlesinger N. Gastrointestinal involvement in polyarteritis nodosa. Clin Gastroenterol Hepatol 2008; 6:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/8\">",
"      Buffo GC, Deitch JS. Pneumatosis intestinalis in a patient with polyarteritis nodosa. Gastrointest Radiol 1986; 11:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/9\">",
"      Lee EL, Smith HJ, Miller GL 3rd, et al. Ischemic pseudomembranous colitis with perforation due to polyarteritis nodosa. Am J Gastroenterol 1984; 79:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/10\">",
"      Levine SM, Hellmann DB, Stone JH. Gastrointestinal involvement in polyarteritis nodosa (1986-2000): presentation and outcomes in 24 patients. Am J Med 2002; 112:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/11\">",
"      Zizic TM, Classen JN, Stevens MB. Acute abdominal complications of systemic lupus erythematosus and polyarteritis nodosa. Am J Med 1982; 73:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/12\">",
"      Fauci AS, Katz P, Haynes BF, Wolff SM. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 1979; 301:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/13\">",
"      Kruger M, B&ouml;ker KH, Zeidler H, Manns MP. Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon alfa-2b. J Hepatol 1997; 26:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/14\">",
"      Carpenter MT, West SG. Polyarteritis nodosa in hairy cell leukemia: treatment with interferon-alpha. J Rheumatol 1994; 21:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/15\">",
"      Glasier CM, Siegel MJ, McAlister WH, Shackelford GD. Henoch-Schonlein syndrome in children: gastrointestinal manifestations. AJR Am J Roentgenol 1981; 136:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/16\">",
"      Goldman LP, Lindenberg RL. Henoch-schoenlein purpura. Gastrointestinal manifestations with endoscopic correlation. Am J Gastroenterol 1981; 75:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/17\">",
"      Blanco R, Mart&iacute;nez-Taboada VM, Rodr&iacute;guez-Valverde V, et al. Henoch-Sch&ouml;nlein purpura in adulthood and childhood: two different expressions of the same syndrome. Arthritis Rheum 1997; 40:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/18\">",
"      Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/19\">",
"      Cappell MS. Esophageal necrosis and perforation associated with the anticardiolipin antibody syndrome. Am J Gastroenterol 1994; 89:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/20\">",
"      Gaspari JC, Sande JR, Thomas CF Jr, et al. Lupus anticoagulant masquerading as an acute abdomen with multiorgan involvement. Am J Gastroenterol 1995; 90:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/21\">",
"      Cappell MS. Atypical duodenal ulcer associated with the antiphospholipid antibody syndrome. Am J Gastroenterol 1997; 92:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/22\">",
"      Richardson SC, Willis J, Wong RC. Ischemic colitis, systemic lupus erythematosus, and the lupus anticoagulant: case report and review. Gastrointest Endosc 2003; 57:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/23\">",
"      Lockshin MD. Antiphospholipid antibody. Babies, blood clots, biology. JAMA 1997; 277:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/24\">",
"      Babian M, Nasef S, Soloway G. Gastrointestinal infarction as a manifestation of rheumatoid vasculitis. Am J Gastroenterol 1998; 93:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/25\">",
"      Griffin JW Jr, Harrison HB, Tedesco FJ, Mills LR 4th. Behcet's disease with multiple sites of gastrointestinal involvement. South Med J 1982; 75:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/26\">",
"      Anti M, Marra G, Rapaccini GL, et al. Esophageal involvement in Beh&ccedil;et's syndrome. J Clin Gastroenterol 1986; 8:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/27\">",
"      Powderly WG, Lombard MG, Murray FE, et al. Oesophageal ulceration in Beh&ccedil;et's disease presenting with haemorrhage. Ir J Med Sci 1987; 156:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/28\">",
"      Stringer DA, Cleghorn GJ, Durie PR, et al. Beh&ccedil;et's syndrome involving the gastrointestinal tract--a diagnostic dilemma in childhood. Pediatr Radiol 1986; 16:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/29\">",
"      Le Thi Huong D, Wechsler B, Dell'Isola B, et al. Acute pancreatitis in Beh&ccedil;et's disease. Dig Dis Sci 1992; 37:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/30\">",
"      Wakefield AJ, Ekbom A, Dhillon AP, et al. Crohn's disease: pathogenesis and persistent measles virus infection. Gastroenterology 1995; 108:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/31\">",
"      Zlatanic J, Fleisher M, Sasson M, et al. Crohn's disease and acute leukocytoclastic vasculitis of skin. Am J Gastroenterol 1996; 91:2410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/32\">",
"      Lupi-Herrera E, S&aacute;nchez-Torres G, Marcushamer J, et al. Takayasu's arteritis. Clinical study of 107 cases. Am Heart J 1977; 93:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/33\">",
"      Arend WP, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990; 33:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/34\">",
"      Jafri FM, Mendelow H, Shadduck RK, Sekas G. Jejunal vasculitis with protein-losing enteropathy after bone marrow transplantation. Gastroenterology 1990; 98:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/35\">",
"      Perlemuter G, Chaussade S, Soubrane O, et al. Multifocal stenosing ulcerations of the small intestine revealing vasculitis associated with C2 deficiency. Gastroenterology 1996; 110:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/36\">",
"      Gaburri PD, Assis RV, Ferreira LE. Intestinal ulcers due to drug-induced perinuclear anti-neutrophilic cytoplasmic antibody-positive vasculitis and antiphospholipid syndrome. Clin Gastroenterol Hepatol 2005; 3:A28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/37\">",
"      Khurshid Y, Kathula S, Hillman N, et al. A case of bleeding jejunal ulcer due to vasculitis from hydroxyurea. Am J Gastro 2000; 95:2616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/38\">",
"      Seibold F, Slametschka D, Gregor M, Weber P. Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1994; 107:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/39\">",
"      Bansi DS, Fleming KA, Chapman RW. Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis: prevalence, titre, and IgG subclass. Gut 1996; 38:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/40\">",
"      Mulder AH, Horst G, Haagsma EB, et al. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology 1993; 17:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/41\">",
"      Schmidt WA. Use of imaging studies in the diagnosis of vasculitis. Curr Rheumatol Rep 2004; 6:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/42\">",
"      Harre RG, Conrad GR, Seabold JE. Colonic localization of indium-111 labeled leukocytes in active Behcet's disease. Clin Nucl Med 1988; 13:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24968/abstract/43\">",
"      Stancanelli B, Vita A, Vinci M, et al. Bleeding of small bowel in Henoch-Sch&ouml;nlein syndrome: the successful diagnostic role of video capsule endoscopy. Am J Med 2006; 119:82.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8229 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-110.137.129.113-14BEEF5253-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_24_24968=[""].join("\n");
var outline_f24_24_24968=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10733896\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SPECIFIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Churg-Strauss syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10734207\">",
"      Rheumatoid vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Beh&ccedil;et's disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Inflammatory bowel disease associated vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Takayasu arteritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Jejunal vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Drug-induced vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EVALUATION OF THE PATIENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10733896\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/8229\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/8229|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/54/36705\" title=\"diagnostic image 1\">",
"      Renal arteriogram in polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/8229|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/49/8985\" title=\"picture 1\">",
"      Polyarteritis nodosa (light micrograph)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/2/23599\" title=\"picture 2\">",
"      IgA nephropathy IF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/20/43333\" title=\"picture 3A\">",
"      Leukocytoclastic vasculitis I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/37/23126\" title=\"picture 3B\">",
"      Leukocytoclastic vasculitis II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44377?source=related_link\">",
"      Acute mesenteric ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33206?source=related_link\">",
"      Chronic mesenteric ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/19/13624?source=related_link\">",
"      Clinical features and diagnosis of Takayasu arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=related_link\">",
"      Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=related_link\">",
"      Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=related_link\">",
"      Clinical manifestations and diagnosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=related_link\">",
"      Clinical manifestations and diagnosis of rheumatoid vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=related_link\">",
"      Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=related_link\">",
"      Clinical manifestations and natural history of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5928?source=related_link\">",
"      Gastrointestinal manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41350?source=related_link\">",
"      Skin and eye manifestations of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28119?source=related_link\">",
"      Treatment and prognosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33498?source=related_link\">",
"      Treatment of Beh&ccedil;et&rsquo;s disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=related_link\">",
"      Treatment of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_24_24969="Treatment of community-acquired pneumonia in adults in the outpatient setting";
var content_f24_24_24969=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of community-acquired pneumonia in adults in the outpatient setting",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/24/24969/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/24/24969/contributors\">",
"     Thomas M File, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/24/24969/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/24/24969/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/24/24969/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/24/24969/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/24/24969/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Community-acquired pneumonia (CAP) is defined as an acute infection of the pulmonary parenchyma in a patient who has acquired the infection in the community, as distinguished from hospital-acquired (nosocomial) pneumonia (HAP). A third category of pneumonia, designated healthcare-associated pneumonia (HCAP), is acquired in other healthcare facilities such as nursing homes, dialysis centers, and outpatient clinics.",
"   </p>",
"   <p>",
"    CAP is a common and potentially serious illness. It is associated with considerable morbidity and mortality, particularly in elderly patients and those with significant comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1801?source=see_link\">",
"     \"Prognosis of community-acquired pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of CAP in adults in the outpatient setting will be reviewed here. A variety of other important issues related to CAP are discussed separately. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnostic approach to patients with CAP. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link\">",
"       \"Diagnostic approach to community-acquired pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      How one makes the decision to admit patients with CAP to the hospital. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38473?source=see_link\">",
"       \"Community-acquired pneumonia in adults: Risk stratification and the decision to admit\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment recommendations for CAP in patients requiring hospitalization. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=see_link\">",
"       \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment recommendations for patients with healthcare-associated pneumonia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=see_link\">",
"       \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The evidence for efficacy of different antibiotic medications in the empiric treatment of CAP and issues related to drug resistance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29210?source=see_link\">",
"       \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The epidemiology and microbiology of CAP. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=see_link\">",
"       \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pneumonia in special populations, such as aspiration pneumonia and immunocompromised patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31017?source=see_link\">",
"       \"Aspiration pneumonia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21273?source=see_link\">",
"       \"Pulmonary infections in immunocompromised patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR HOSPITALIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determination of whether a patient with community-acquired pneumonia (CAP) can be safely treated as an outpatient or requires hospitalization is essential before selecting an antibiotic regimen. Severity of illness is the most critical factor in making this determination, but other factors should also be taken into account. These include ability to maintain oral intake, likelihood of compliance, history of substance abuse, cognitive impairment, living situation, and patient functional status. These issues with appropriate references are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38473?source=see_link\">",
"     \"Community-acquired pneumonia in adults: Risk stratification and the decision to admit\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly, prediction rules have been developed to assist in the decision of site of care for CAP. The two most commonly used prediction rules are the Pneumonia Severity Index (PSI) and CURB-65. The PSI is better studied and validated, but requires a more complicated assessment (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?43/42/44705?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    CURB-65 uses five prognostic variables (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?40/62/41952?source=see_link\">",
"     calculator 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       C",
"      </strong>",
"      onfusion (based upon a specific mental test or disorientation to person, place, or time)",
"     </li>",
"     <li>",
"      <strong>",
"       U",
"      </strong>",
"      rea (blood urea nitrogen in the United States) &gt;7",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"     </li>",
"     <li>",
"      <strong>",
"       R",
"      </strong>",
"      espiratory rate &gt;30",
"      <span class=\"nowrap\">",
"       breaths/minute",
"      </span>",
"     </li>",
"     <li>",
"      <strong>",
"       B",
"      </strong>",
"      lood pressure [BP] (systolic &lt;90 mmHg or diastolic &lt;60 mmHg)",
"     </li>",
"     <li>",
"      Age &gt;",
"      <strong>",
"       65",
"      </strong>",
"      years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors of the original CURB-65 report suggested that patients with a CURB-65 score of 0 to 1, who comprised 45 percent of the original cohort and 61 percent of the later cohort, were at low risk and could probably be treated as outpatients; those with a score of 2 should be admitted to the hospital, and those with a score of 3 or more should be assessed for ICU care, particularly if the score was 4 or 5.",
"   </p>",
"   <p>",
"    A simplified version (CRB-65), which does not require testing for blood urea nitrogen, may be appropriate for decision-making in primary care practitioners' offices. In this version, admission to the hospital is recommended if one or more points are present.",
"   </p>",
"   <p>",
"    Clinical judgment should be used for all patients, incorporating the prediction rule scores as a component of the decision for hospitalization or intensive care unit admission, but not as an absolute determinant [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF ANTIMICROBIAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Community-acquired pneumonia (CAP) can be caused by a variety of pathogens, with bacteria being the most common identifiable cause (",
"    <a class=\"graphic graphic_table graphicRef72014 \" href=\"UTD.htm?8/18/8495\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. The choice of initial therapy is complicated by the emergence of antibiotic resistance among Streptococcus pneumoniae, the most common bacterium responsible for CAP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\", section on 'Microbiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29210?source=see_link&amp;anchor=H16#H16\">",
"     \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\", section on 'Drug resistance and choice of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Empiric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic therapy is typically begun on an empiric basis, since the causative organism is not identified in an appreciable proportion of cases of CAP treated in the outpatient setting (",
"    <a class=\"graphic graphic_table graphicRef72014 \" href=\"UTD.htm?8/18/8495\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. In addition, the clinical features and chest radiographic findings are not sufficiently specific to determine etiology and influence treatment decisions. The sputum Gram stain can be useful for directing the choice of initial therapy if performed on a good quality sample and interpreted by skilled examiners using appropriate criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link&amp;anchor=H9#H9\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\", section on 'Sputum'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2007 Infectious Diseases Society of",
"    <span class=\"nowrap\">",
"     America/American",
"    </span>",
"    Thoracic Society",
"    <span class=\"nowrap\">",
"     (IDSA/ATS)",
"    </span>",
"    guidelines on the management of CAP suggest that routine tests to identify an etiology for CAP are optional for patients who do not require hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/2\">",
"     2",
"    </a>",
"    ]. This recommendation is based in part upon the low rate of failure of empiric therapy in patients with CAP treated in the outpatient setting. The efficacy of empiric therapy was illustrated in a study of over 700 ambulatory patients treated for CAP in one of six emergency departments seen from November 2000 through April 2001, in which empiric antibiotics (a macrolide or fluoroquinolone in &gt;88 percent) were almost universally effective, with only 2.2 percent requiring hospitalization within three weeks of initial emergency department visit [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, testing for a microbial diagnosis is important in clinical or epidemiologic settings suggesting possible infection with an organism that requires treatment different from standard empiric regimens. These include Legionella species, Mycobacterium tuberculosis, influenza A and B or avian influenza, community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA), or agents of bioterrorism [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17591?source=see_link&amp;anchor=H6#H6\">",
"     \"Sputum cultures for the evaluation of bacterial pneumonia\", section on 'Community-acquired pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The selection of antimicrobial regimens for empiric therapy is based upon a number of factors, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most likely pathogen(s). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Common pathogens'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Clinical trials proving efficacy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29210?source=see_link\">",
"       \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Risk factors for antimicrobial resistance. The choice of empiric therapy must take into account the emergence of antibiotic resistance among S. pneumoniae, one of the most common bacteria responsible for CAP. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Risk factors for drug resistance'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Medical comorbidities that may influence the likelihood of a specific pathogen and may be a risk factor for treatment failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional factors that may affect the choice of antimicrobial regimen include the potential for inducing antimicrobial resistance, pharmacokinetic and pharmacodynamic properties, safety profile, and cost [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Common pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a variety of bacterial pathogens can cause CAP, a limited number are responsible for the majority of cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With respect to patients treated in the outpatient setting, the most frequently isolated pathogens are S. pneumoniae, Mycoplasma pneumoniae, Chlamydophila pneumoniae, and respiratory viruses (eg, influenza, parainfluenza, respiratory syncytial virus) (",
"    <a class=\"graphic graphic_table graphicRef72014 \" href=\"UTD.htm?8/18/8495\">",
"     table 1",
"    </a>",
"    ). Legionella pneumoniae and Haemophilus influenzae are less common. The \"atypical\" pathogens are not often identified in clinical practice because there are not specific, rapid, or standardized tests for their detection, with the exception of L. pneumophila. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38199?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Legionella infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with CAP due to S. aureus, Enterobacteriaceae, and Pseudomonas aeruginosa are typically sicker and require admission to the hospital. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of community-acquired pneumonia in adults who require hospitalization\", section on 'Common pathogens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Risk factors for drug resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for and other issues related to drug resistance in patients with CAP are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29210?source=see_link&amp;anchor=H16#H16\">",
"     \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\", section on 'Drug resistance and choice of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly, risk factors for drug-resistant S. pneumoniae in adults include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &gt;65 years",
"     </li>",
"     <li>",
"      Beta-lactam, macrolide, or fluoroquinolone therapy within the past three to six months",
"     </li>",
"     <li>",
"      Alcoholism",
"     </li>",
"     <li>",
"      Medical comorbidities",
"     </li>",
"     <li>",
"      Immunosuppressive illness or therapy",
"     </li>",
"     <li>",
"      Exposure to a child in a day care center",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recent therapy or a repeated course of therapy with beta-lactams, macrolides, or fluoroquinolones is a risk factor for pneumococcal resistance to the same class of antibiotic.",
"   </p>",
"   <p>",
"    The impact of discordant drug therapy, which refers to treatment of an infection with an antimicrobial agent to which the causative organism has demonstrated in vitro resistance, appears to vary with antibiotic class and possibly with specific agents within a class. Most studies have been performed in patients with S. pneumoniae infection and suggest that current levels of beta-lactam resistance generally do not cause treatment failure when appropriate agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    ) and doses are used. Of the beta-lactams,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    is a possible exception. In addition, there appears to be an increased risk of macrolide failure in patients with macrolide-resistant S. pneumoniae. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29210?source=see_link&amp;anchor=H18#H18\">",
"     \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\", section on 'Outcomes with discordant drug therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/15/19704?source=see_link&amp;anchor=H2#H2\">",
"     \"Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamines, and ketolides\", section on 'Macrolides and azalides'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of medical societies have issued guidelines for the treatment of community-acquired pneumonia (CAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/2,9,10\">",
"     2,9,10",
"    </a>",
"    ]. The antibiotic regimens advocated by a collaboration between the Infectious Disease Society of America and the American Thoracic Society",
"    <span class=\"nowrap\">",
"     (IDSA/ATS)",
"    </span>",
"    in 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/2\">",
"     2",
"    </a>",
"    ], and guidelines from the British Thoracic Society (BTS) in 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/9\">",
"     9",
"    </a>",
"    ] are summarized in tables 1 and 2, respectively (",
"    <a class=\"graphic graphic_table graphicRef71665 \" href=\"UTD.htm?42/46/43757\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74382 \" href=\"UTD.htm?13/43/14013\">",
"     table 3",
"    </a>",
"    ). Both guidelines note problems with the emergence of drug-resistant S. pneumoniae (DRSP).",
"   </p>",
"   <p>",
"    The following discussion will review antibiotic therapy in ambulatory patients with CAP. Guideline recommendations for therapy of patients with CAP treated in the inpatient setting are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The regimens chosen by the",
"      <span class=\"nowrap\">",
"       IDSA/ATS",
"      </span>",
"      guidelines mainly rely on macrolides (with or without a beta-lactam) or newer fluoroquinolones for outpatient therapy (",
"      <a class=\"graphic graphic_table graphicRef71665 \" href=\"UTD.htm?42/46/43757\">",
"       table 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/2\">",
"       2",
"      </a>",
"      ]. The guidelines promote the use of macrolides to provide coverage for both S. pneumoniae and atypical pathogens (particularly, M. pneumoniae and C. pneumoniae), which account for the majority of cases of CAP in ambulatory patients (",
"      <a class=\"graphic graphic_table graphicRef72014 \" href=\"UTD.htm?8/18/8495\">",
"       table 1",
"      </a>",
"      ). In studies from different regions of the world, atypical pathogens account for 20 to 30 percent of cases of CAP [",
"      <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The BTS guidelines tend to select older antibiotics than those recommended in North America (",
"      <a class=\"graphic graphic_table graphicRef74382 \" href=\"UTD.htm?13/43/14013\">",
"       table 3",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     North American approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The macrolides, which are effective against the atypical pathogens, are recommended in the absence of significant risk factors for macrolide-resistant S. pneumoniae. Experience in North America suggests that macrolide-resistant S. pneumoniae is less significant for patients without comorbidities or risk factors compared with patients with risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/8,12,13\">",
"     8,12,13",
"    </a>",
"    ]. Recent use of antibiotics is considered a risk factor for resistant S. pneumoniae; thus, monotherapy with a macrolide is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for persons who received an antibiotic in the preceding three months.",
"   </p>",
"   <p>",
"    In addition, since the rate of macrolide resistance among pneumococci is &gt;25 percent in virtually all areas of the United States and in certain other regions worldwide (",
"    <a class=\"external\" href=\"file://www.cddep.org/ResistanceMap/bug-drug/SP-ML\">",
"     file://www.cddep.org/ResistanceMap/bug-drug/SP-ML",
"    </a>",
"    ), we also recommend",
"    <strong>",
"     not",
"    </strong>",
"    using monotherapy with a macrolide if there is evidence to suggest pneumococcal pneumonia (eg, positive pneumococcal urine antigen, positive gram stain or culture, or acute onset of illness associated with fever and chills). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/15/19704?source=see_link&amp;anchor=H2#H2\">",
"     \"Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamines, and ketolides\", section on 'Macrolides and azalides'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29210?source=see_link&amp;anchor=H20#H20\">",
"     \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\", section on 'Macrolide resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     BTS approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 2009 British Thoracic Society guidelines, the preferred drug for outpatient management is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    (500 mg orally three times daily), with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    as alternatives, including for those with penicillin allergy (",
"    <a class=\"graphic graphic_table graphicRef74382 \" href=\"UTD.htm?13/43/14013\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rationale is that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    at these doses is effective against most strains of S. pneumoniae with decreased susceptibility to penicillin. Most of the macrolide-resistant S. pneumoniae in Europe is erm-mediated high-level resistance. As a result, the macrolides are not optimal first-line empiric agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29210?source=see_link&amp;anchor=H20#H20\">",
"     \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\", section on 'Macrolide resistance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/15/19704?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamines, and ketolides\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Coverage of atypical pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The BTS approach places less significance than the North American approach on the need to treat the atypical pathogens empirically in ambulatory patients. Initial empiric therapy that covers M. pneumoniae is considered unnecessary, since the pathogen exhibits epidemic periodicity every four to five years and largely affects younger persons.",
"   </p>",
"   <p>",
"    Although the clinical course of M. pneumoniae or C. pneumoniae infection is often self-limited, these pathogens can cause severe CAP. As a result, it has been argued that appropriate treatment for even mild CAP due to Mycoplasma reduces both morbidity and the duration of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/5/3162?source=see_link\">",
"     \"Mycoplasma pneumoniae infection in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of empiric coverage of atypical pathogens was evaluated in a 2005 meta-analysis that evaluated 18 randomized trials of over 6700 patients with mild to moderate CAP who were assigned to treatment with either a beta-lactam or an antibiotic active against atypical pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/15\">",
"     15",
"    </a>",
"    ]. There was no overall advantage to covering atypical pathogens in terms of the rate of failure to achieve clinical cure or improvement (relative risk 0.97, 95% CI 0.87-1.07) but, in a subgroup analysis, there was a significantly lower failure rate for Legionella infection with such a regimen (relative risk 0.40, 95% CI 0.19-0.85). These trials were not designed to compare the time to response with the different regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT REGIMENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment regimens for outpatients with community-acquired pneumonia (CAP) are based upon studies of the effectiveness of antibiotics, the severity of illness, the presence of comorbid conditions, and the prevalence of risk factors for drug resistant S. pneumoniae (DRSP). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29210?source=see_link\">",
"     \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest the following approach to empiric antimicrobial therapy. Pathogen-specific therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/4/13386?source=see_link\">",
"     \"Pneumococcal pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/5/3162?source=see_link\">",
"     \"Mycoplasma pneumoniae infection in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7270?source=see_link\">",
"     \"Pneumonia caused by Chlamydophila (Chlamydia) pneumoniae in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33015?source=see_link\">",
"     \"Treatment and prevention of Legionella infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31494?source=see_link\">",
"     \"Pseudomonas aeruginosa pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     No comorbidities or recent antibiotic use",
"    </span>",
"    &nbsp;&mdash;&nbsp;For uncomplicated pneumonia in patients who do not require hospitalization, have no significant comorbidities",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    use of antibiotics within the last three months, and where there is not a high prevalence of macrolide-resistant strains, we recommend any one of the following oral regimens:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       Azithromycin",
"      </a>",
"      (500 mg on day one followed by four days of 250 mg a day); 500 mg a day for three days, or 2 g single dose (microsphere formulation) are acceptable alternative regimens",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      XL (two 500 mg tablets once daily) for five days or until afebrile for 48 to 72 hours",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      (100 mg twice a day) for 7 to 10 days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is concern that widespread use of fluoroquinolones in outpatients will promote the development of fluoroquinolone-resistance among respiratory pathogens (as well as other colonizing pathogens) and may lead to an increased incidence of C. difficile colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/16\">",
"     16",
"    </a>",
"    ]. In addition, empiric use of fluoroquinolones should not be used for patients at risk for Mycobacterium tuberculosis without an appropriate assessment for tuberculosis infection. The administration of a fluoroquinolone in patients with tuberculosis has been associated with a delay in diagnosis, increase in resistance, and poor outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29210?source=see_link&amp;anchor=H21#H21\">",
"     \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\", section on 'Fluoroquinolone resistance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link&amp;anchor=H5#H5\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\", section on 'Antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of these concerns, the use of fluoroquinolones is discouraged in ambulatory patients with CAP without comorbid conditions or recent antimicrobial use, unless it is known that there is a high prevalence of high-level macrolide-resistant S. pneumoniae in the local community. When such resistance is present, the regimen for patients with comorbidities or recent antibiotic use described in the next section can be followed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29210?source=see_link&amp;anchor=H20#H20\">",
"     \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\", section on 'Macrolide resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite these recommendations, fluoroquinolones continue to be given, often inappropriately, for CAP. In one report of 768 ambulatory patients with CAP seen in an emergency department in 2000 and 2001, 245 (32 percent) were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ; one-half of these patients did not meet the criteria for appropriate fluoroquinolone therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both the macrolides and the fluoroquinolones can cause a prolonged QT interval, which can result in torsades de pointes.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    have been associated with a small, absolute increase in cardiovascular mortality (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=see_link&amp;anchor=H22#H22\">",
"     \"Azithromycin, clarithromycin, and telithromycin\", section on 'Long QT syndrome'",
"    </a>",
"    ). For patients with known QT interval prolongation or risk factors for QT interval prolongation, we favor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    since it has not been associated with QT interval prolongation. However, doxycycline should be avoided during pregnancy. It should also be noted that doxycycline has been less well studied for the treatment of CAP than the macrolides or fluoroquinolones. Risk factors for QT interval prolongation include advanced age, hypokalemia, hypomagnesemia, clinically significant bradycardia, and the use of other agents that prolong the QT interval, including class IA (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ) and class III (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ) antiarrhythmic agents and certain azoles (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=see_link&amp;anchor=H30#H30\">",
"     \"Fluoroquinolones\", section on 'QT interval prolongation and arrhythmia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=see_link&amp;anchor=H22#H22\">",
"     \"Azithromycin, clarithromycin, and telithromycin\", section on 'Long QT syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H34#H34\">",
"     \"Pharmacology of azoles\", section on 'Selected clinical effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     Telithromycin",
"    </a>",
"    is",
"    <strong>",
"     not",
"    </strong>",
"    recommended as a first-line empiric regimen because of concerns about toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=see_link&amp;anchor=H12#H12\">",
"     \"Azithromycin, clarithromycin, and telithromycin\", section on 'Warnings about telithromycin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Comorbidities or recent antibiotic use",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of significant comorbidities (ie, chronic obstructive pulmonary disease [COPD], liver or renal disease, cancer, diabetes, chronic heart disease, alcoholism, asplenia, or immunosuppression),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    use of antibiotics within the prior three months, increases the risk of infection with more resistant pathogens. We recommend one of the following oral regimens for such patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A respiratory fluoroquinolone (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"       gemifloxacin",
"      </a>",
"      320 mg daily,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      750 mg daily, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      400 mg daily) for a minimum of five days. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment duration and response'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Combination therapy with a beta-lactam effective against S. pneumoniae (high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      , 1 g three times daily or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"       amoxicillin-clavulanate",
"      </a>",
"      2 g twice daily or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27333?source=see_link\">",
"       cefpodoxime",
"      </a>",
"      200 mg twice daily or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"       cefuroxime",
"      </a>",
"      500 mg twice daily)",
"      <strong>",
"       PLUS",
"      </strong>",
"      either a macrolide (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      500 mg on day one followed by four days of 250 mg a day or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      250 mg twice daily or clarithromycin XL 1000 mg once daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg twice daily). Treatment should be continued for a minimum of five days. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment duration and response'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These regimens are also appropriate where there is a high prevalence of \"high-level\" macrolide-resistant S. pneumoniae, even in the absence of comorbidity or recent antimicrobial use. As noted above, for non-pregnant patients with known QT interval prolongation or risk factors for QT interval prolongation, we favor combination therapy with a beta-lactam plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    in order to avoid the QT interval-prolonging effects of fluoroquinolones and macrolides. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'No comorbidities or recent antibiotic use'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Because",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    is more effective in vitro against most strains of H. influenzae than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , azithromycin is preferred for outpatients with comorbidities such as chronic obstructive pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"     Gemifloxacin",
"    </a>",
"    causes a rash in 2.8 percent of patients overall, but a higher rate (14 percent) in women under 40 years of age who received the drug for seven or more days; the incidence is much lower when used for the recommended five-day duration. The rash is generally mild, occurs after the fifth day of therapy, and resolves with discontinuation of the agent. The rash is not associated with phototoxicity or hypersensitivity and does not preclude the use of other fluoroquinolones in the future, although repeated courses of gemifloxacin should be avoided in such patients. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"     \"Gemifloxacin: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     Telithromycin",
"    </a>",
"    should be reserved as an option for patients at risk for drug-resistant pneumococcal infection in whom alternative agents are not appropriate. However, it should",
"    <strong>",
"     not",
"    </strong>",
"    be prescribed in patients with known liver disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=see_link&amp;anchor=H12#H12\">",
"     \"Azithromycin, clarithromycin, and telithromycin\", section on 'Warnings about telithromycin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pathogen-directed therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the etiology of CAP has been identified using reliable microbiologic methods, antimicrobial therapy should be directed at that pathogen (",
"    <a class=\"graphic graphic_table graphicRef64816 \" href=\"UTD.htm?19/63/20478\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Treatment duration and response",
"    </span>",
"    &nbsp;&mdash;&nbsp;With respect to treatment duration, we generally agree with the 2007",
"    <span class=\"nowrap\">",
"     IDSA/ATS",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/2\">",
"     2",
"    </a>",
"    ]. Ambulatory patients with CAP should be treated for a minimum of five days; because of the prolonged half-life of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , a shorter duration of drug administration may be indicated for this agent. Appropriate dosing regimens for azithromycin in patients without comorbidities are discussed above. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'No comorbidities or recent antibiotic use'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Support for this recommendation comes from two meta-analyses of randomized controlled trials of patients with mild to moderate CAP, which found comparable clinical outcomes with less than seven days compared with more than seven days of antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. One of the meta-analyses included trials in which short courses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    were compared with longer courses of therapy of other agents [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/17\">",
"     17",
"    </a>",
"    ]; this is important to note since azithromycin has a long half-life and therefore a short duration of therapy does not necessarily translate into a short period of antimicrobial activity. However, the second meta-analysis did not include trials in which azithromycin was used and compared treatment with the same agents but for different durations of therapy, and suggested that a short course of these other antimicrobial agents is sufficient for mild to moderate CAP [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/18\">",
"     18",
"    </a>",
"    ]. Antibiotic therapy should not be stopped until the patient is afebrile for 48 to 72 hours and is clinically stable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29210?source=see_link&amp;anchor=H25#H25\">",
"     \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\", section on 'Duration of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients with CAP begin to improve soon after the initiation of appropriate antibiotic therapy as evidenced by resolution of symptoms, physical findings, and laboratory signs of active infection (",
"    <a class=\"graphic graphic_table graphicRef74599 \" href=\"UTD.htm?3/31/3579\">",
"     table 5",
"    </a>",
"    ). However, some symptoms often persist as the patient convalesces [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. This was illustrated in a study of sequential interviews in 134 ambulatory patients with CAP [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/19\">",
"     19",
"    </a>",
"    ]. The median time to resolution ranged from three days for fever to 14 days for both cough and fatigue. At least one symptom (eg, cough, fatigue, dyspnea) was still present at 28 days in one-third of patients. In another report, 76 percent had at least one symptom at 30 days, most commonly fatigue, compared to 45 percent by history in the one month prior to the onset of CAP [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These symptoms are usually not sufficient to interfere with work as illustrated in a review of 399 ambulatory patients with CAP in which the median time of return to work was six days even though one-third had at least one persistent symptom at 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1801?source=see_link&amp;anchor=H2#H2\">",
"     \"Prognosis of community-acquired pneumonia in adults\", section on 'Mortality and symptom resolution'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Persistence of such symptoms is not an indication to extend the course of antibiotic therapy as long as the patient has demonstrated some clinical response to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Follow-up chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest x-ray findings usually clear more slowly than clinical manifestations (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of community-acquired pneumonia in adults who require hospitalization\", section on 'Radiographic response'",
"    </a>",
"    ). Routine chest x-rays for follow-up of CAP patients who are responding clinically are unnecessary. Some authorities recommend a follow-up chest x-ray at 7 to 12 weeks after treatment for selected patients who are over age 40 years or are smokers, to document resolution of the pneumonia and exclude underlying diseases, such as malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     The nonresponding patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;General issues relating to nonresolving pneumonia are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23945?source=see_link\">",
"     \"Nonresolving pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with CAP, nonresponse is primarily seen in those who require hospitalization, occurring in 6 to 15 percent of such patients. The incidence of treatment failure is not well defined in ambulatory patients with CAP because population-based studies would be required [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=see_link&amp;anchor=H22#H22\">",
"     \"Treatment of community-acquired pneumonia in adults who require hospitalization\", section on 'The nonresponding patient'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     VACCINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CAP should be appropriately vaccinated for influenza and pneumococcal infection. Screening for influenza vaccination status is warranted during influenza season (eg, from October through March in the northern hemisphere) in all patients. Screening for pneumococcal vaccination status is warranted in patients age 65 or older or with other indications for vaccination (such as presence of comorbidity or smoking). Vaccination can be performed during outpatient treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SMOKING CESSATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking cessation should be a goal for patients with CAP who smoke [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24969/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=see_link\">",
"       \"Patient information: Pneumonia in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/38/30308?source=see_link\">",
"       \"Patient information: Pneumonia in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most initial treatment regimens for community-acquired pneumonia (CAP) are empiric. A limited number of pathogens are responsible for the majority of cases of CAP (",
"      <a class=\"graphic graphic_table graphicRef72014 \" href=\"UTD.htm?8/18/8495\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Principles of antimicrobial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Emerging drug-resistant Streptococcus pneumoniae (DRSP) complicates the use of empiric treatment. Treatment failures have been demonstrated with use of macrolides for macrolide-resistant organisms. We recommend",
"      <strong>",
"       not",
"      </strong>",
"      prescribing macrolide monotherapy for patients who have received an antibiotic within the preceding three months or if the local rate of macrolide resistance is &gt;25 percent or if there are findings to suggest pneumococcal pneumonia (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'North American approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite in vitro resistance, penicillin-resistant pneumococci may respond to higher dose beta-lactams other than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"       cefuroxime",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Risk factors for drug resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      North American and British guidelines differ in their recommendations for first-line therapy for outpatient pneumonia. British guidelines promote",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      and place less significance on atypical pathogens. North American guidelines advocate treating both atypical pathogens and pneumococcus, and suggest macrolides or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      when antibiotic resistance is not anticipated. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Guidelines'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Coverage of atypical pathogens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For uncomplicated pneumonia in patients who have",
"      <strong>",
"       no",
"      </strong>",
"      significant comorbidities",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      risk factors for macrolide resistance (use of antibiotics within the last three months, local rate of macrolide resistance &gt;25 percent, or evidence to suggest pneumococcal pneumonia), we suggest treatment with an advanced macrolide (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). Regimens include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (500 mg on day one followed by four days of 250 mg a day, or 500 mg for three days, or 2 g as single dose microsphere regimen) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      XL (two 500 mg tablets once daily). We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      as an alternative to a macrolide, especially in non-pregnant patients at risk for QT interval prolongation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest",
"      <strong>",
"       not",
"      </strong>",
"      using fluoroquinolones for uncomplicated ambulatory patients with CAP (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'No comorbidities or recent antibiotic use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For non-hospitalized patients with comorbidities or recent antibiotic use, we suggest treatment with a fluoroquinolone as monotherapy, or combination therapy with a beta-lactam plus either a macrolide or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). For non-pregnant patients at risk for QT interval prolongation, we favor combination therapy with a beta-lactam plus doxycycline in order to avoid the QT interval-prolonging effects of fluoroquinolones and macrolides. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Comorbidities or recent antibiotic use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Outpatients with CAP should be treated for a minimum of five days, although a shorter duration may be indicated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      because of its prolonged half-life. Therapy should not be stopped until the patient is afebrile for 48 to 72 hours and is clinically stable. When this is achieved, the persistence of other symptoms (eg, dyspnea, cough) is not an indication to extend the course of antibiotic therapy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment duration and response'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24969/abstract/1\">",
"      File TM. Community-acquired pneumonia. Lancet 2003; 362:1991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24969/abstract/2\">",
"      Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24969/abstract/3\">",
"      Marrie TJ, Shariatzadeh MR. Community-acquired pneumonia requiring admission to an intensive care unit: a descriptive study. Medicine (Baltimore) 2007; 86:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24969/abstract/4\">",
"      Marrie TJ, Poulin-Costello M, Beecroft MD, Herman-Gnjidic Z. Etiology of community-acquired pneumonia treated in an ambulatory setting. Respir Med 2005; 99:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24969/abstract/5\">",
"      Lim WS, Macfarlane JT, Boswell TC, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001; 56:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24969/abstract/6\">",
"      Read RC. Evidence-based medicine: empiric antibiotic therapy in community-acquired pneumonia. J Infect 1999; 39:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24969/abstract/7\">",
"      Malcolm C, Marrie TJ. Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting. Arch Intern Med 2003; 163:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24969/abstract/8\">",
"      File TM Jr, Niederman MS. Antimicrobial therapy of community-acquired pneumonia. Infect Dis Clin North Am 2004; 18:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24969/abstract/9\">",
"      Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64 Suppl 3:iii1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24969/abstract/10\">",
"      Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000; 31:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24969/abstract/11\">",
"      Arnold FW, Summersgill JT, Lajoie AS, et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med 2007; 175:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24969/abstract/12\">",
"      Vanderkooi OG, Low DE, Green K, et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24969/abstract/13\">",
"      Daneman N, McGeer A, Green K, et al. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis 2006; 43:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24969/abstract/14\">",
"      File TM Jr, Garau J, Blasi F, et al. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest 2004; 125:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24969/abstract/15\">",
"      Mills GD, Oehley MR, Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ 2005; 330:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24969/abstract/16\">",
"      Chalmers JD, Al-Khairalla M, Short PM, et al. Proposed changes to management of lower respiratory tract infections in response to the Clostridium difficile epidemic. J Antimicrob Chemother 2010; 65:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24969/abstract/17\">",
"      Li JZ, Winston LG, Moore DH, Bent S. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med 2007; 120:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24969/abstract/18\">",
"      Dimopoulos G, Matthaiou DK, Karageorgopoulos DE, et al. Short- versus long-course antibacterial therapy for community-acquired pneumonia : a meta-analysis. Drugs 2008; 68:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24969/abstract/19\">",
"      Metlay JP, Atlas SJ, Borowsky LH, Singer DE. Time course of symptom resolution in patients with community-acquired pneumonia. Respir Med 1998; 92:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24969/abstract/20\">",
"      Marrie TJ, Beecroft MD, Herman-Gnjidic Z. Resolution of symptoms in patients with community-acquired pneumonia treated on an ambulatory basis. J Infect 2004; 49:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24969/abstract/21\">",
"      Fine MJ, Stone RA, Singer DE, et al. Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. Arch Intern Med 1999; 159:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24969/abstract/22\">",
"      Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000; 31:347.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7031 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-7484D81656-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_24_24969=[""].join("\n");
var outline_f24_24_24969=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR HOSPITALIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRINCIPLES OF ANTIMICROBIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Common pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Risk factors for drug resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      North American approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      BTS approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Coverage of atypical pathogens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      No comorbidities or recent antibiotic use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Comorbidities or recent antibiotic use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pathogen-directed therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Treatment duration and response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Follow-up chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      The nonresponding patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      VACCINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SMOKING CESSATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7031\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7031|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/18/8495\" title=\"table 1\">",
"      Microbiology CAP site of care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/46/43757\" title=\"table 2\">",
"      IDSA ATS CAP guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/43/14013\" title=\"table 3\">",
"      BTS CAP guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/63/20478\" title=\"table 4\">",
"      Pathogen-directed therapy for CAP in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/31/3579\" title=\"table 5\">",
"      Duration of pneumonia findings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?43/42/44705?source=related_link\" title=\"calculator 1\">",
"      Calculator: Community-acquired pneumonia severity index (PSI) for adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?40/62/41952?source=related_link\" title=\"calculator 2\">",
"      Calculator: CURB-65 pneumonia severity score",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29210?source=related_link\">",
"      Antibiotic studies for the treatment of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31017?source=related_link\">",
"      Aspiration pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=related_link\">",
"      Azithromycin, clarithromycin, and telithromycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38199?source=related_link\">",
"      Clinical manifestations and diagnosis of Legionella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=related_link\">",
"      Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38473?source=related_link\">",
"      Community-acquired pneumonia in adults: Risk stratification and the decision to admit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=related_link\">",
"      Fluoroquinolones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=related_link\">",
"      Gemifloxacin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/5/3162?source=related_link\">",
"      Mycoplasma pneumoniae infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23945?source=related_link\">",
"      Nonresolving pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/38/30308?source=related_link\">",
"      Patient information: Pneumonia in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=related_link\">",
"      Patient information: Pneumonia in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/4/13386?source=related_link\">",
"      Pneumococcal pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7270?source=related_link\">",
"      Pneumonia caused by Chlamydophila (Chlamydia) pneumoniae in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1801?source=related_link\">",
"      Prognosis of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31494?source=related_link\">",
"      Pseudomonas aeruginosa pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21273?source=related_link\">",
"      Pulmonary infections in immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/15/19704?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamines, and ketolides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17591?source=related_link\">",
"      Sputum cultures for the evaluation of bacterial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33015?source=related_link\">",
"      Treatment and prevention of Legionella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults who require hospitalization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=related_link\">",
"      Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_24_24970="Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease";
var content_f24_24_24970=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/24/24970/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/24/24970/contributors\">",
"     Georgios I Papaioannou, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/24/24970/contributors\">",
"     Gary V Heller, MD, PhD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/24/24970/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/24/24970/contributors\">",
"     Ami E Iskandrian, MD, MACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/24/24970/contributors\">",
"     Patricia A Pellikka, MD, FACC, FAHA, FASE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/24/24970/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/24/24970/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/24/24970/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 22, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise radionuclide myocardial perfusion imaging (rMPI) can, via the presence and extent of perfusion defects, be used to demonstrate the presence of coronary heart disease (CHD) and to risk stratify and guide management of patients with known disease. The utility of scintigraphic imaging with exercise in these settings will be reviewed here.",
"   </p>",
"   <p>",
"    General discussions on the use of stress testing for the diagnosis and prognosis of known or suspected CHD, including its prognostic role after an acute coronary syndrome or revascularization, and the advantages and limitations of the different stress tests are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=see_link\">",
"     \"Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/30/44520?source=see_link\">",
"     \"Selecting the optimal cardiac stress test\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHOICE OF TEST MODALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice among the different types of stress tests is based upon the patient's ability to exercise to a level high enough to produce meaningful results on exercise ECG testing, the possible presence of baseline electrocardiographic abnormalities that could interfere with the interpretation of exercise ECG testing, and whether or not it is important to localize ischemia or assess myocardial viability (",
"    <a class=\"graphic graphic_algorithm graphicRef71324 \" href=\"UTD.htm?26/52/27470\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef58852 \" href=\"UTD.htm?23/60/24512\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In patients who are able to exercise and achieve an adequate heart rate (defined as &ge;85 percent of their age-predicted maximum heart rate), double product (defined as product of peak systolic blood pressure and heart rate &ge;20,000) or workload (defined as &ge;80 percent functional aerobic capacity), treadmill or bicycle exercise is the preferred form of stress because it provides the most information concerning patient symptoms, cardiovascular function, and the hemodynamic response during usual forms of activity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The inability to perform an exercise test is in itself a negative prognostic factor in patients with CHD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H10#H10\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Exercise capacity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Comparison of test performance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports have reviewed the published literature comparing exercise rMPI to exercise ECG testing and to other forms of stress imaging. A meta-analysis compared the performance of the following tests in patients with an intermediate pretest risk of CHD (25 to 75 percent): exercise ECG testing, planar thallium imaging, SPECT perfusion imaging, stress echocardiography, and positron emission tomography (PET), each of which was followed by coronary angiography if the test was positive [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following values for sensitivity and specificity were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise ECG testing &mdash; 68 and 77 percent in 132 studies of over 24,000 patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=see_link\">",
"       \"Performance of exercise ECG testing\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Planar thallium rMPI (including both exercise and pharmacologic testing) &mdash; 79 and 73 percent in six studies of 510 patients.",
"     </li>",
"     <li>",
"      Thallium SPECT rMPI (including both exercise and pharmacologic testing) &mdash; 88 and 77 percent in 10 studies of 1174 patients",
"     </li>",
"     <li>",
"      Stress echocardiography &mdash; 76 and 88 percent in six studies of 510 patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=see_link\">",
"       \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      PET scanning &mdash; 91 and 82 percent in three studies of 206 patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a second meta-analysis, 44 articles met criteria for determining the sensitivity and specificity (compared to coronary angiography) of exercise SPECT rMPI and exercise echocardiography for the diagnosis of CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/4\">",
"     4",
"    </a>",
"    ]. The two tests had similar sensitivity (85 and 87 percent), but the specificity was significantly lower (ie, more false positives) with exercise rMPI (64 versus 77 percent).",
"   </p>",
"   <p>",
"    A number of studies have compared simultaneous stress echocardiography and stress rMPI. The diagnostic accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/5-8\">",
"     5-8",
"    </a>",
"    ] and prognostic value [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/9,10\">",
"     9,10",
"    </a>",
"    ] of the two techniques were comparable.",
"   </p>",
"   <p>",
"    The relative accuracy of stress echocardiography and stress rMPI may be influenced by certain patient characteristics. As examples, stress echocardiography appears to be more accurate than stress rMPI in patients with left ventricular hypertrophy, while vasodilator stress rMPI may be superior in patients with high body mass index. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=see_link&amp;anchor=H15#H15\">",
"     \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\", section on 'Left ventricular hypertrophy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prediction of event-free survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above observations evaluated the test performance of stress testing compared to coronary angiography. A separate issue is stress testing as a predictor of event-free survival.",
"   </p>",
"   <p>",
"    Among patients with known or suspected CHD, the negative predictive value of the test is important since a negative test may end the need for further diagnostic testing and allow the clinician to reassure the patient of",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    low risk for a cardiovascular event in the near future.",
"   </p>",
"   <p>",
"    In a meta-analysis of studies that evaluated event-free survival following exercise stress imaging with either rMPI or echocardiography in patients with known or suspected CHD, the negative predictive value for MI and cardiac death was 99 and 98 percent, respectively, over about three years in both men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perhaps the most serious potential hindrance to the accuracy of stress echocardiography is that the images obtained with echocardiography are subjectively interpreted with an accuracy that is dependent upon clinician experience [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/11\">",
"     11",
"    </a>",
"    ], while radionuclide myocardial perfusion imaging lends itself well to semi-automated computer quantification, increasing both accuracy and reproducibility. However, interobserver variability for each technique is low in experienced laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Summary and ACC/AHA guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the sensitivity of exercise ECG testing is lower than in other forms of stress testing [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/3\">",
"     3",
"    </a>",
"    ]. Despite this limitation, it remains widely used in patients who can exercise to a level high enough to produce meaningful results and do not have ECG abnormalities that might interfere with interpretation. The strengths of exercise ECG testing are its: lower cost; and, with use of a risk score such as the Duke treadmill score, the ability to identify patients (particularly men) at low and high clinical risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H11#H11\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Duke treadmill score'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When an imaging test is performed, the choice between scintigraphy and echocardiography should be based upon local availability and expertise [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/3,14\">",
"     3,14",
"    </a>",
"    ]. In patients who are able to exercise, treadmill or bicycle exercise is the preferred form of stress because it provides the most information concerning patient symptoms, cardiovascular function, and the hemodynamic response during usual forms of activity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/1,2,15\">",
"     1,2,15",
"    </a>",
"    ]. The inability to perform an exercise test is in itself a negative prognostic factor in patients with CHD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H10#H10\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Exercise capacity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2002 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on chronic stable angina and on exercise testing published recommendations for the use of stress imaging as the initial test for diagnosis or for risk assessment in patients (",
"    <a class=\"graphic graphic_algorithm graphicRef58852 \" href=\"UTD.htm?23/60/24512\">",
"     algorithm 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/1,2,15\">",
"     1,2,15",
"    </a>",
"    ]. The guidelines concluded that there was evidence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    general agreement (class I) that, among patients with known or suspected CHD who are able to exercise to a level high enough to produce meaningful results on exercise ECG testing, exercise rMPI might be used as the",
"    <strong>",
"     initial test",
"    </strong>",
"    for diagnosis or for risk stratification in selected settings (",
"    <a class=\"graphic graphic_table graphicRef52995 \" href=\"UTD.htm?17/42/18093\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74428 \" href=\"UTD.htm?32/46/33516\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=see_link\">",
"     \"Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise rMPI or exercise echocardiography in patients who do not have left bundle branch block or a paced ventricular rhythm but have other resting ECG abnormalities that could interfere with the interpretation of exercise ECG testing (preexcitation syndrome or more than 1 mm ST depression at rest).",
"     </li>",
"     <li>",
"      Exercise rMPI or exercise echocardiography in patients with prior revascularization (percutaneous coronary intervention or coronary artery bypass graft surgery).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When used for diagnosis, stress testing of any form is primarily of value in patients with an",
"    <strong>",
"     intermediate",
"    </strong>",
"    pretest probability (variably defined as between 25 and 75 percent or between 10 and 90 percent) of CHD (",
"    <a class=\"graphic graphic_table graphicRef53433 \" href=\"UTD.htm?6/8/6284\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For prognosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise rMPI or exercise echocardiography to identify the extent, severity, and location of ischemia in patients with an intermediate pretest probability of disease who do not have left bundle branch block or a paced ventricular rhythm but are taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      or have resting ECG abnormalities that could interfere with the interpretation of exercise ECG testing.",
"     </li>",
"     <li>",
"      Exercise rMPI or exercise echocardiography to assess the functional significance of coronary lesions, in not already known, when planning percutaneous coronary intervention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The guidelines concluded that the evidence was less well established (class IIb) for exercise rMPI or exercise echocardiography as the initial diagnostic test in patients who are taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    or have left ventricular hypertrophy who have less than 1 mm of ST depression on the baseline ECG. A class IIb rating was also given to any form of stress imaging in patients who have a normal baseline ECG and are not taking digoxin in whom exercise ECG testing is the preferred initial test (",
"    <a class=\"graphic graphic_algorithm graphicRef58852 \" href=\"UTD.htm?23/60/24512\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Exercise rMPI was considered not to be useful (class III) in the presence of left bundle branch block or a paced ventricular rhythm. In such patients, exercise is associated with an appreciable incidence of transient positive defects in the anteroseptal and septal regions in the absence of a lesion within the left anterior descending coronary artery. Stress testing in patients with LBBB or with a paced ventricular rhythm is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28743?source=see_link\">",
"     \"Stress testing in patients with left bundle branch block or a paced ventricular rhythm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TECHNICAL ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Study protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise rMPI is typically performed with concurrent ECG monitoring. The exercise protocol is the same as that used for exercise ECG testing alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=see_link\">",
"     \"Performance of exercise ECG testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Choice of isotope",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, two 99m-Tc-labeled perfusion agents are primarily used for clinical testing: 99m-Tc-sestamibi and 99m-Tc-tetrofosmin. These agents have improved imaging characteristics compared to 201-Tl due to higher photon energy and shorter half-life. Perhaps most important, they allow easy ECG gated acquisition (gated SPECT imaging), permitting the simultaneous evaluation of left ventricular systolic function and myocardial perfusion and the identification of attenuation artifacts (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/11,12,16\">",
"     11,12,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One limitation to gated SPECT measurement of LVEF after stress is that moderate to severe stress-induced ischemia can cause myocardial stunning [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. As a result, the poststress LVEF may not reflect true left ventricular function at rest if only a poststress scan is obtained. In one report, the poststress LVEF was more than 5 percent lower than resting values in 36 percent of patients with reversible perfusion defects [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8759?source=see_link\">",
"     \"Clinical syndromes of stunned or hibernating myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differences in test performance with 201-Tl and 99m-Tc for the diagnosis of CHD are discussed below. (See",
"    <a class=\"local\" href=\"#H14\">",
"     '201-Tl versus 99m-Tc'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Attenuation artifacts and correction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attenuation artifacts decrease the specificity of SPECT imaging. 99m-Tc gated SPECT imaging permits the assessment of systolic wall thickening at end-diastole and end-systole on multiple SPECT tomograms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/16\">",
"     16",
"    </a>",
"    ]. Normal systolic thickening and wall motion in a fixed defect on both rest and stress images represents an attenuation artifact rather than a myocardial scar. In contrast, a fixed defect representing myocardial scar is associated with reduced thickening and hypokinesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/10/25768?source=see_link\">",
"     \"Attenuation artifact in SPECT radionuclide myocardial perfusion imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The application of attenuation correction for photon attenuation and scatter in SPECT rMPI improves diagnostic accuracy by reducing the number of false-positive results [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. This was illustrated in a prospective multicenter clinical trial [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/19\">",
"     19",
"    </a>",
"    ]. The normalcy rate was used as a surrogate for specificity; it is defined as the rate of normal perfusion scans in patients with &lt;5 percent likelihood of CHD on the basis of clinical and ECG stress data (",
"    <a class=\"graphic graphic_table graphicRef53433 \" href=\"UTD.htm?6/8/6284\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The application of",
"    <span class=\"nowrap\">",
"     attenuation/scatter",
"    </span>",
"    correction and resolution compensation significantly improved the normalcy rate compared to uncorrected perfusion data using either the corrected images (96 versus 86 percent) or the corrected data and quantitative analysis (97 percent versus 86 percent). There was no reduction in overall sensitivity (75 to 78 percent), although the detection of multivessel disease was reduced.",
"   </p>",
"   <p>",
"    A 2002 position statement from the American Society of Nuclear Cardiology (ASNC) describes pertinent information regarding the methods of attenuation correction, application, and quality control [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/10/25768?source=see_link\">",
"     \"Attenuation artifact in SPECT radionuclide myocardial perfusion imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EXERCISE RMPI FOR DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Test performance",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a meta-analysis cited above, planar thallium rMPI had an overall sensitivity and specificity of 79 and 73 percent, respectively, while thallium SPECT rMPI had greater sensitivity and similar specificity (88 and 77 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/3\">",
"     3",
"    </a>",
"    ]. However, these data included both exercise and pharmacologic testing.",
"   </p>",
"   <p>",
"    The performance of exercise 201-Tl SPECT rMPI was evaluated in a review of 1441 patients combined from six studies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The sensitivity averaged 90 percent (range 82 to 98 percent) overall and 85 percent in patients without a prior history of CHD. As with planar imaging, the sensitivity varied with the extent of CHD, ranging from 83 percent for the detection of single vessel disease to 93 percent for two vessel disease to 95 percent for three vessel disease.",
"     </li>",
"     <li>",
"      The specificity averaged 70 percent (range 43 to 91 percent). The low specificity was thought to at least in part reflect referral bias, since patients with abnormal tests were more frequently referred for coronary angiography than patients with normal tests. This explanation was further supported by the high normalcy rate (89 percent), which is defined as the rate of normal perfusion scans in patients with &lt;5 percent likelihood of CHD on the basis of clinical and ECG stress data (",
"      <a class=\"graphic graphic_table graphicRef53433 \" href=\"UTD.htm?6/8/6284\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The current consensus is that SPECT imaging has superior sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/3,22\">",
"     3,22",
"    </a>",
"    ] that is partially due to its ability to detect an individual stenosis via localization of stress-induced perfusion defects [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/22\">",
"     22",
"    </a>",
"    ]. There are a number of variables that increase sensitivity with rMPI. These include [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Known or extensive CHD",
"     </li>",
"     <li>",
"      High-grade coronary stenosis",
"     </li>",
"     <li>",
"      Proximal location of stenosis",
"     </li>",
"     <li>",
"      Presence of wall motion abnormalities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are also variables that diminish the sensitivity for CHD detection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Single vessel disease",
"     </li>",
"     <li>",
"      Left circumflex coronary stenosis",
"     </li>",
"     <li>",
"      Branch vessel or distal stenosis",
"     </li>",
"     <li>",
"      Mild degree of stenosis (&lt;50 percent luminal narrowing)",
"     </li>",
"     <li>",
"      Inadequate heart rate response during exercise",
"     </li>",
"     <li>",
"      Concurrent antianginal therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of attenuation correction technology to reduce attenuation artifacts and improve specificity is described above. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Attenuation artifacts and correction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Exercise level",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who undergo exercise ECG testing, a diagnostic test that fails to achieve 85 to 90 percent of the patient's predicted maximal heart rate is considered inadequate to rule out ischemic heart disease if the test is otherwise negative (ie, absence of chest discomfort or ECG findings) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=see_link&amp;anchor=H25#H25\">",
"     \"Performance of exercise ECG testing\", section on 'Test endpoints'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar considerations apply to exercise rMPI. This was illustrated in a report in which 164 patients who achieved adequate exercise end points were compared to 108 patients who had submaximal exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/25\">",
"     25",
"    </a>",
"    ]. On 201-Tl SPECT imaging, submaximal exercise was associated with a significantly lower rate of perfusion defects consistent with ischemia in patients with coronary disease involving one (56 versus 35 percent), two (58 versus 80 percent), or three vessels (56 versus 88 percent).",
"   </p>",
"   <p>",
"    A more direct assessment of the importance of adequate exercise was performed in another study in which 22 patients with known CHD underwent both the usual symptom-limited incremental exercise test and, more than two days later, a submaximal test at 70 percent of the predicted maximal heart rate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/26\">",
"     26",
"    </a>",
"    ]. On 201-Tl planar imaging, reversible defects were induced in all patients during incremental exercise and all but two during submaximal exercise. However, the size of the ischemic area and the degree of ischemia were significantly lower during submaximal exercise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     201-Tl versus 99m-Tc",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of small studies have directly compared the diagnostic accuracy of 201-Tl and 99m-Tc rMPI [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. A pooled comparative analysis of studies of exercise SPECT imaging with 99m-Tc-sestamibi and 201-Tl found that 99m-Tc-sestamibi was associated with increases in sensitivity (90 versus 82 percent), specificity (93 versus 80 percent), and normalcy (100 versus 77 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Somewhat different results were noted in a study published after the comparative analysis in which the diagnostic accuracy of 201-Tl and 99m-Tc-sestamibi SPECT were prospectively compared in 115 women (85 with suspected CHD and 30 volunteers with a low pretest likelihood of CHD) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/30\">",
"     30",
"    </a>",
"    ]. All underwent both perfusion (201-Tl and 99m-Tc-sestamibi) and ECG gated 99m-Tc-sestamibi SPECT imaging, and the majority also underwent coronary angiography. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall sensitivities of the 201-Tl and 99m-Tc-sestamibi perfusion studies were similar for detecting &ge;50 percent stenoses (75 and 72 percent) and &ge;70 percent stenoses (84 versus 80 percent).",
"     </li>",
"     <li>",
"      The specificity was significantly lower with 201-Tl imaging for detecting &ge;50 percent stenoses (71 versus 86 and 94 percent for 99m-Tc-sestamibi perfusion and 99m-Tc-sestamibi gated SPECT, respectively). A similar difference was noted for detecting &ge;70 percent stenoses (67 versus 84 and 92 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based in part upon these observations, two 99m-Tc-labeled perfusion agents are primarily used for clinical testing: 99m-Tc-sestamibi and 99m-Tc-tetrofosmin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Dual versus single isotope imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dual-isotope imaging approach, described in 1993, consists of rest",
"    <span class=\"nowrap\">",
"     201-Tl/stress",
"    </span>",
"    99m-Tc-sestamibi SPECT imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/32\">",
"     32",
"    </a>",
"    ]. In this protocol, 3 mCi of 201-Tl is injected at rest, with images acquired 10 minutes later. Subsequently, an exercise test is performed with 25 to 30 mCi of 99m-Tc-sestamibi injected at peak stress.",
"   </p>",
"   <p>",
"    The dual-isotope separate acquisition approach was validated in patients with a previous myocardial infarction who underwent a rest 99m-Tc-sestamibi in addition to the dual isotope SPECT study and, to determine sensitivity and specificity, coronary angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/32\">",
"     32",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dual-isotope SPECT was highly sensitive for detecting &ge;50 percent coronary artery stenoses (91 percent) and &ge;70 percent stenoses (96 percent).",
"     </li>",
"     <li>",
"      Although high values for specificity were recorded (75 percent for &lt;50 percent stenoses, and 82 percent for &lt;70 percent stenoses), the significance was uncertain given the small number of patients with normal coronary angiograms. However, the normalcy rate was 95 percent, which is higher than seen with 201-Tl (about 89 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/21\">",
"       21",
"      </a>",
"      ] and similar to that seen with 99m-Tc-sestamibi SPECT studies [",
"      <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients assessed for defect reversibility, segmental agreement for defect type between rest 201-Tl in the dual isotope study and rest 99m-Tc-sestamibi was 97 percent in zones without previous infarction, 98 percent in infarct zones, 95 percent for defect reversibility pattern (normal, reversible, or nonreversible), and 86 percent for the exact segmental score.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to its use for diagnosis, dual-isotope imaging also has prognostic value that is additive to other parameters. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Exercise rMPI for prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An alternative to dual-isotope imaging is single-isotope imaging using a technetium-based radiopharmaceutical. In many laboratories, throughput is addressed by stressing the patient immediately upon completion of the rest study if a",
"    <span class=\"nowrap\">",
"     rest/stress",
"    </span>",
"    protocol is being used. This is accomplished by injecting three times the radiopharmaceutical at stress in relation to the resting dose, thereby offsetting residual radionuclide.",
"   </p>",
"   <p>",
"    Single-isotope imaging has several advantages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Flexibility of performing",
"      <span class=\"nowrap\">",
"       rest/stress,",
"      </span>",
"      one-day",
"      <span class=\"nowrap\">",
"       stress/rest",
"      </span>",
"      or two-day",
"      <span class=\"nowrap\">",
"       stress/rest,",
"      </span>",
"      and finally stress-only imaging with attenuation correction. Thus, the laboratory can choose the most appropriate protocol for an individual patient.",
"     </li>",
"     <li>",
"      Interpretation of images is easier since the same isotope is used for both rest and stress. This is particularly important for interpreting attenuation artifact when attenuation correction is not available with gated SPECT imaging. Furthermore, several algorithms for attenuation correction are validated only with technetium and not thallium.",
"     </li>",
"     <li>",
"      The presence or absence of transient ischemic cavity dilation, a specific marker for multivessel coronary artery disease and poor prognosis, can be determined much more easily with single isotope protocols [",
"      <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When technetium-based products were first released, the issue of myocardial viability assessment with rest redistribution thallium was an argument in favor of dual-isotope imaging. However, optimizing the dual-isotope protocol for viability requires that a separate rest thallium scan be obtained at least four hours after the initial injection. Furthermore, several studies have validated both 99m-Tc sestamibi and tetrofosmin as equivalent to rest redistribution 201-Tl for the assessment of myocardial viability [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23066?source=see_link\">",
"     \"Assessment of myocardial viability by nuclear imaging in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiation exposure is an important consideration in the determination of which stress protocol to use in the laboratory (single isotope versus dual isotope versus thallium-201). In one review summarizing the radiation exposure of various noninvasive and invasive cardiovascular imaging procedures, the following estimated radiation doses were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dual-isotope imaging (thallium and technetium) &mdash; approximately 25 to 30 mSV",
"     </li>",
"     <li>",
"      Single isotope",
"      <span class=\"nowrap\">",
"       rest/stress",
"      </span>",
"      technetium imaging &mdash; approximately 8 to 10 mSV",
"     </li>",
"     <li>",
"      Single isotope",
"      <span class=\"nowrap\">",
"       rest/stress",
"      </span>",
"      thallium-201 imaging &mdash; approximately 18 to 20 mSV",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While radiation dose is not a major issue for patients undergoing a single",
"    <span class=\"nowrap\">",
"     rest/stress",
"    </span>",
"    imaging study, the cumulative exposure in patients receiving multiple imaging studies is a potential concern.",
"   </p>",
"   <p>",
"    In a statement published by the American Society of Nuclear Cardiology, several methods to reduce radiation exposure were recommended (",
"    <a class=\"graphic graphic_algorithm graphicRef52470 \" href=\"UTD.htm?32/5/32862\">",
"     algorithm 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/36\">",
"     36",
"    </a>",
"    ]. First, dual isotope imaging on a routine basis is strongly discouraged. The exception is for the assessment of myocardial viability. Similarly, single-isotope thallium-201 imaging is also strongly discouraged from routine use, again with the exception of assessment of myocardial viability. The use of technetium for either single isotope in the form of",
"    <span class=\"nowrap\">",
"     rest/stress",
"    </span>",
"    imaging or single isotope imaging in the form of stress-only imaging is recommended. In addition, positron emission tomography (PET) perfusion imaging is strongly recommended as the radiation exposure is even lower than for single isotope technetium imaging (PET 4-6 mSV). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23066?source=see_link&amp;anchor=H14#H14\">",
"     \"Assessment of myocardial viability by nuclear imaging in coronary heart disease\", section on 'Positron emission tomography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stress-only imaging, particularly with exercise, is an attractive option for reducing radiation exposure. The concept is that by performing stress imaging (with attenuation correction) first, if the study is completely normal or markedly abnormal, no rest imaging (and hence no additional radiation) is necessary. A clinical update of stress-only imaging recommends this approach, particularly in patients with no known coronary artery disease or in patients with coronary disease without prior myocardial infarction or bypass surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/37\">",
"     37",
"    </a>",
"    ]. Of importance, the prognosis of patients with normal stress-only imaging, particularly with exercise as the stress agent, is outstanding, with less than a 1 percent annual rate of cardiac events [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/38\">",
"     38",
"    </a>",
"    ]. This event rate is similar to that of",
"    <span class=\"nowrap\">",
"     rest/stress",
"    </span>",
"    SPECT imaging. Thus, stress-only imaging, particularly with attenuation correction, should be a strong consideration for patients eligible for exercise RMPI.",
"   </p>",
"   <p>",
"    Data have demonstrated that the use of attenuation correction to determine attenuation artifact has been validated for technetium-based imaging agents but not thallium-201 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/39\">",
"     39",
"    </a>",
"    ]. With this information, patients with no known coronary artery disease can efficiently undergo stress-only imaging using technetium-based imaging agents [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Studies suggest that stress-only imaging using ECG-gating and attenuation correction can correctly identify normal and abnormal patients without using rest imaging in a very high percentage. Furthermore, patients with normal stress-only imaging studies discharged from the Emergency Department have an excellent prognosis, giving further validation of the approach [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/41\">",
"     41",
"    </a>",
"    ]. Stress-only imaging not only improves efficiency but also reduces radiation exposure.",
"   </p>",
"   <p>",
"    Thus, the original concepts supporting the superiority of dual-isotope imaging are no longer valid, and the increased flexibility of single isotope imaging may be important in certain laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Left main coronary artery disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 60 percent of patients with left main disease have multiple thallium defects, and almost 50 percent have increased lung uptake of thallium. These findings are not very sensitive [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. As an example, the presence of only one abnormal coronary artery territory on exercise thallium imaging does not exclude extensive disease. In one report of 264 such patients who underwent angiography, 26 percent had three-vessel or left main disease on coronary angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/44\">",
"     44",
"    </a>",
"    ]. However, when the exercise thallium findings are combined with the blood pressure and ECG response to exercise, the sensitivity for extensive disease can be as high as 86 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Special settings",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     LBBB or paced ventricular rhythm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise rMPI in patients with LBBB is associated with an appreciable incidence of transient defects in the anteroseptal and septal regions in the absence of a lesion within the left anterior descending coronary artery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/45\">",
"     45",
"    </a>",
"    ]. Stress testing in patients with LBBB or with a paced ventricular rhythm is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28743?source=see_link\">",
"     \"Stress testing in patients with left bundle branch block or a paced ventricular rhythm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     EXERCISE RMPI FOR PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined myocardial perfusion and function results from stress rMPI can distinguish patients at high risk (more than 5 percent annual mortality rate) from those at intermediate risk (1 to 5 percent annual mortality rate) or low risk (less than 1 percent annual mortality rate) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following discussion will emphasize the predictive value in patients with known or suspected CHD. The general role of stress testing for prognosis and risk stratification with rMPI in patients who have had an acute coronary syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6678?source=see_link\">",
"     \"Radionuclide myocardial perfusion imaging in predischarge risk stratification of medically treated patients with non-ST elevation acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with any modality of exercise testing, bad prognostic signs include poor exercise capacity (&lt;5 METs); exercise-induced angina; abnormally low peak systolic blood pressure (&lt;130 mmHg) or a fall in the systolic blood pressure during exercise; and chronotropic incompetence [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. The presence and extent of perfusion defects on rMPI provides additional prognostic value [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/47,48,50-53\">",
"     47,48,50-53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of functional capacity was illustrated in a review of 3400 consecutive patients with suspected CHD who underwent symptom-limited exercise thallium stress testing [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/47\">",
"     47",
"    </a>",
"    ]. At two year follow-up in this low risk population, the overall mortality was 3.2 percent. The presence of fair or poor functional capacity (&lt;6 METs) was the strongest predictor of all-cause mortality (relative risk 4.0); the presence of thallium perfusion defects was a significant but less powerful predictor (relative risk 1.2 for each two additional segments with a defect) (",
"    <a class=\"graphic graphic_figure graphicRef68509 \" href=\"UTD.htm?35/13/36062\">",
"     figure 1",
"    </a>",
"    ). Reduced functional capacity and the extent of ischemia or the thallium score were also predictive of cardiac mortality (relative risks 4.4 and 1.6, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Normal rMPI",
"    </span>",
"    &nbsp;&mdash;&nbsp;A normal 201-Tl or 99m-Tc-sestamibi scan is generally associated with low risk of future cardiac events (less than 1 percent per year) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/50,53-60\">",
"     50,53-60",
"    </a>",
"    ]. One report, for example, evaluated 5183 consecutive patients with known or suspected CHD who underwent resting thallium SPECT and an exercise or pharmacologic stress sestamibi SPECT [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/50\">",
"     50",
"    </a>",
"    ]. At 1.8 year follow-up, the 2946 patients with a normal scan had a low risk for cardiac death or myocardial infarction (&le;0.5 and &le;0.3 percent per year, respectively) (",
"    <a class=\"graphic graphic_figure graphicRef64441 \" href=\"UTD.htm?19/40/20110\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Among patients with a normal scan, the prognosis is worse in those with known CHD or diabetes and in males and older patients. The magnitude of these relationships was illustrated in a review of 7376 consecutive patients with a normal exercise or adenosine rMPI [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/61\">",
"     61",
"    </a>",
"    ]. An 80 year old man with diabetes and known CHD had a relatively high rate of cardiac death or MI at two years (4.9 percent), while a 50 year old woman without diabetes or known CHD was at minimal risk (0.1 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     With exercise ECG testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relatively benign prognosis persists even in patients with a significantly abnormal exercise ECG test or angiographically significant coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/53-55,57,62\">",
"     53-55,57,62",
"    </a>",
"    ]. An initial report evaluated 156 patients with a strongly positive exercise ECG test (ST depression &gt;2 mm, mostly in the inferior and lateral leads) and a normal exercise rMPI [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/57\">",
"     57",
"    </a>",
"    ]. At a mean follow-up of 34 months, there were no deaths or nonfatal infarctions.",
"   </p>",
"   <p>",
"    The interaction between a normal exercise rMPI and exercise ECG testing was subsequently evaluated in a much larger study of 4649 subjects with known or suspected CHD who were at intermediate risk based upon exercise treadmill testing (Duke treadmill score -10 to 4) but had a normal or near-normal rMPI [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/55\">",
"     55",
"    </a>",
"    ]. Cardiovascular survival and cardiac survival free of MI at seven years were 99 and 97 percent, respectively. Seven-year cardiac survival was lower (89 percent) in those with cardiac enlargement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H11#H11\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Duke treadmill score'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Abnormal rMPI",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-risk features on rMPI predicting an increased risk of cardiac events include extensive ischemia involving more than 20 percent of the left ventricle, defects in more than one coronary vascular supply region, reversible ischemia in multiple segments, transient or persistent left ventricular cavity dilatation, and increased lung uptake of thallium or sestamibi, a marker of exercise-induced left ventricular dysfunction that is best assessed by obtaining a five minute post-stress and four hour redistribution or rest anterior planar scan before the initiation of SPECT imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/33,46,50,53,63-65\">",
"     33,46,50,53,63-65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The predictive value of an abnormal test was demonstrated in the analysis cited above of 5183 consecutive patients with known or suspected CHD who underwent resting thallium SPECT and an exercise or pharmacologic stress sestamibi SPECT [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/50\">",
"     50",
"    </a>",
"    ]. At 1.8 years, there were 119 cardiac deaths. For patients with normal, mildly abnormal, moderately abnormal, or severely abnormal perfusion defects, the annual rate of cardiac death was 0.5, 2.7, 2.9, and 4.2 percent, respectively (",
"    <a class=\"graphic graphic_figure graphicRef64441 \" href=\"UTD.htm?19/40/20110\">",
"     figure 2",
"    </a>",
"    ). Similar results on all-cause mortality have been reported following SPECT MPI in a cohort of 2225 women followed for nearly four years, in whom an abnormal SPECT MPI result was associated with significantly greater all-cause mortality (13.1 versus 4.0 percent in patients with normal SPECT MPI findings) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical factors can affect the relationship between the findings on exercise ECG and exercise rMPI. This was illustrated in a review of 1461 symptomatic patients with a low risk (&ge;+5) Duke treadmill score [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/56\">",
"     56",
"    </a>",
"    ]. A clinical score was determined by giving one point each of typical angina, a history of myocardial infarction, diabetes, insulin use, and male gender and one point for each decade over age 40; a clinical score &ge;5 denoted high risk and was present in 21 percent of patients.",
"   </p>",
"   <p>",
"    Seven year survival was 99 percent in the patients with a low risk clinical score (&lt;5), independent of whether the perfusion scan was normal, mildly abnormal, or severely abnormal. Among the minority of patients with a high risk clinical score, seven year survival was 94 percent with a normal or mildly abnormal scan and 84 percent with a severely abnormal scan.",
"   </p>",
"   <p>",
"    The presence of post-stress left ventricular dysfunction has a significant impact on the predictive value of rMPI. This was illustrated in a series of 1680 consecutive patients with known or suspected CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/67\">",
"     67",
"    </a>",
"    ]. Patients with an LVEF &ge;45 percent had a mortality rate under 1 percent per year, even with severe perfusion abnormalities, while those with an LVEF &lt;45 percent and mild to severe perfusion abnormalities had a mortality rate of 6.6 percent per year.",
"   </p>",
"   <p>",
"    Dual-isotope testing, described above, also has prognostic value as illustrated in a report of 2200 consecutive patients with possible CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/68\">",
"     68",
"    </a>",
"    ]. In this population at overall low risk (1.8 percent at 1.5 years) for \"hard\" events (cardiac death and myocardial infarction), myocardial perfusion SPECT added incremental prognostic information to clinical data and to the Duke treadmill score on exercise ECG testing (",
"    <a class=\"graphic graphic_figure graphicRef53586 \" href=\"UTD.htm?10/5/10334\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=see_link&amp;anchor=H7#H7\">",
"     \"Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease\", section on 'Duke treadmill score'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     EXERCISE RMPI FOR CHOICE OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of inducible ischemia during stress rMPI may help determine which patients with stable CHD will have a survival benefit from revascularization as opposed to medical therapy. The potential predictive value was illustrated in a retrospective study of more than 10,000 consecutive patients without prior MI or revascularization who underwent exercise or adenosine rMPI [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/69\">",
"     69",
"    </a>",
"    ]. Of these patients, 671 underwent revascularization within 60 days after rMPI; the remainder was treated medically. Inducible ischemia and anginal symptoms were the most powerful predictors of mortality. After adjusting for the nonrandomization of treatment, cardiac mortality at two years was significantly lower with revascularization in patients with moderate to severe inducible ischemia (involving more than 10 percent of total myocardium). In contrast, mortality was significantly lower with medical therapy in patients with no or mild inducible ischemia (involving &le;10 percent of total myocardium). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=see_link&amp;anchor=H8#H8\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\", section on 'Strongly positive stress test'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     EXERCISE RMPI IN WOMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have documented the lower diagnostic value of exercise testing in women compared to men. Stress rMPI can improve specificity without compromising sensitivity in the detection of CHD in women compared to exercise ECG testing alone. Exercise SPECT rMPI is more sensitive than planar imaging and the introduction of 99m-Tc agents and the addition of ECG-gated SPECT imaging further improves the specificity compared to 201-Tl imaging. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Technical issues'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The approach to the noninvasive diagnosis of CHD in women, including the role of stress rMPI, is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    .) A 2003 consensus statement from the American Society of Nuclear Cardiology Task Force on Women and Heart Disease describes a stratified approach in women at intermediate to high risk of CHD based upon exercise tolerance, the baseline ECG, and the presence of other comorbidities such as diabetes mellitus (",
"    <a class=\"graphic graphic_algorithm graphicRef60536 \" href=\"UTD.htm?18/47/19199\">",
"     algorithm 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     EXERCISE RMPI IN DIABETES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence, incidence and mortality from all forms of cardiovascular disease are two- to eightfold higher in persons with diabetes. In addition, diabetes in considered a \"coronary risk equivalent\", which means that patients with diabetes belong in the same risk category as patients with known CHD. This conclusion in based in part upon the observation in one report that type 2 diabetics without a prior infarction were at the same risk for myocardial infarction (20 and 19 percent, respectively) and coronary mortality (15 versus 16 percent) as nondiabetics with a prior MI (",
"    <a class=\"graphic graphic_figure graphicRef80251 \" href=\"UTD.htm?34/1/34845\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=see_link\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although early identification of subclinical CHD is desirable in patients with diabetes, there are no data to show a clinical benefit from early detection of CHD in asymptomatic patients. Furthermore, the identification of asymptomatic CHD is not likely to affect therapy since current recommendations include aggressive control of blood pressure and serum LDL-cholesterol and cessation of smoking in all diabetics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The indications for stress rMPI as opposed to exercise ECG testing in patients with diabetes are the same as those that apply to the general population. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Choice of test modality'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The diagnostic accuracy of stress rMPI appears to be similar in diabetics and nondiabetics [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/72\">",
"     72",
"    </a>",
"    ]. Stress rMPI is also an effective tool for risk stratification in patients with diabetes and CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/72-74\">",
"     72-74",
"    </a>",
"    ] and provides incremental prognostic data to exercise ECG testing. This was illustrated in a study of 4755 patients with symptoms of CHD, of whom 929 were diabetic [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/73\">",
"     73",
"    </a>",
"    ]. At 2.5 years, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetic patients had a significantly higher rate of cardiac death or myocardial infarction than nondiabetics (8.6 versus 4.5 percent) and a higher rate of revascularization.",
"     </li>",
"     <li>",
"      Diabetic patients had a higher incidence of abnormal perfusion scans (48 versus 42 percent). An abnormal stress rMPI (71 percent exercise, 29 percent adenosine or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      ) was an independent predictor of cardiac events in both diabetics and nondiabetics, with the highest rate of myocardial infarction (17 percent) seen in diabetics with three-vessel ischemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another report included 1271 diabetic patients and 5862 nondiabetic patients with known or suspected CAD who underwent dual-isotope SPECT imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/72\">",
"     72",
"    </a>",
"    ]. The diabetics had a significantly higher incidence of cardiac death or nonfatal myocardial infarction (4.3 versus 2.3 percent per year). Among the diabetics, the event rate was 1 to 2 percent per year in those with normal scans, 3 to 4 percent per year with mildly abnormal scans, and more than 7 percent per year in patients with moderate to severely abnormal scans.",
"   </p>",
"   <p>",
"    Even worse outcomes have been described in high-risk patients with type 2 diabetes. Among such patients who are unable to exercise (which is an adverse predictor), large perfusion defects have been associated with an annual mortality rate as high as 22 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to the possible role of stress testing, including exercise rMPI, in screening for CHD in patients with diabetes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18761?source=see_link\">",
"     \"Screening for coronary heart disease in patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of rMPI to risk stratify patients with chronic kidney disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=see_link&amp;anchor=H16#H16\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\", section on 'Chronic kidney disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise rMPI is a valuable tool for the evaluation of selected patients with known or suspected CHD. The development of 99m-Tc-labeled agents with improved imaging characteristics and ECG gated acquisition permits simultaneous assessment of myocardial perfusion and left ventricular systolic function. This in turn translates into superior diagnostic accuracy and provides important prognostic information regarding cardiac events. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Technical issues'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Exercise rMPI is an option for diagnosis in patients with an intermediate pretest risk of CHD who are able to exercise but have baseline ECG abnormalities that can interfere with exercise ECG testing (",
"    <a class=\"graphic graphic_table graphicRef52995 \" href=\"UTD.htm?17/42/18093\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Choice of test modality'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Exercise rMPI or exercise echocardiography can provide added prognostic value and can be used to guide therapy in patients who have an intermediate risk exercise ECG test. In comparison, no further evaluation is typically performed in patients with a normal or low risk exercise ECG test (with a possible exception of those at high clinical risk) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/56\">",
"     56",
"    </a>",
"    ], while angiography is typically performed in patients with a high-risk test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=see_link&amp;anchor=H11#H11\">",
"     \"Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease\", section on 'Recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=see_link\">",
"     \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A normal exercise rMPI is associated with a low risk for future cardiac events (&lt;1 percent annual mortality rate). One report, for example, evaluated 5183 consecutive patients with known or suspected CHD who underwent resting thallium SPECT and an exercise or pharmacologic stress sestamibi SPECT [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/50\">",
"     50",
"    </a>",
"    ]. At 1.8-year follow-up, the 2946 patients with a normal scan had a low risk for cardiac death or myocardial infarction (&le;0.5 and &le;0.3 percent per year, respectively) (",
"    <a class=\"graphic graphic_figure graphicRef64441 \" href=\"UTD.htm?19/40/20110\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Normal rMPI'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In contrast, the presence of high-risk findings, such as extensive ischemia, reversible ischemia in multiple segments, transient or persistent cavity dilatation, or an LVEF &lt;45 percent, predict an annual mortality rate above 3 percent. In the study just cited, the annual rate of cardiac death in patients with mildly abnormal, moderately abnormal, or severely abnormal perfusion defects was 2.7, 2.9, and 4.2 percent, respectively (",
"    <a class=\"graphic graphic_figure graphicRef64441 \" href=\"UTD.htm?19/40/20110\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/50\">",
"     50",
"    </a>",
"    ]. High-risk patients should undergo coronary angiography.",
"   </p>",
"   <p>",
"    Exercise rMPI is an effective tool for risk stratification in patients with diabetes and CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. However, the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines do not recommend an imaging study as the initial test for risk stratification in patients who are able to exercise and who do not have baseline ECG abnormalities that could interfere with interpretation of exercise ECG testing (",
"    <a class=\"graphic graphic_table graphicRef74428 \" href=\"UTD.htm?32/46/33516\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/24/24970/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/2\">",
"      Gibbons RJ, Balady GJ, Beasley JW, et al. ACC/AHA Guidelines for Exercise Testing. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). J Am Coll Cardiol 1997; 30:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/3\">",
"      Garber AM, Solomon NA. Cost-effectiveness of alternative test strategies for the diagnosis of coronary artery disease. Ann Intern Med 1999; 130:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/4\">",
"      Fleischmann KE, Hunink MG, Kuntz KM, Douglas PS. Exercise echocardiography or exercise SPECT imaging? A meta-analysis of diagnostic test performance. JAMA 1998; 280:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/5\">",
"      Marwick T, D'Hondt AM, Baudhuin T, et al. Optimal use of dobutamine stress for the detection and evaluation of coronary artery disease: combination with echocardiography or scintigraphy, or both? J Am Coll Cardiol 1993; 22:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/6\">",
"      Qui&ntilde;ones MA, Verani MS, Haichin RM, et al. Exercise echocardiography versus 201Tl single-photon emission computed tomography in evaluation of coronary artery disease. Analysis of 292 patients. Circulation 1992; 85:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/7\">",
"      Forster T, McNeill AJ, Salustri A, et al. Simultaneous dobutamine stress echocardiography and technetium-99m isonitrile single-photon emission computed tomography in patients with suspected coronary artery disease. J Am Coll Cardiol 1993; 21:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/8\">",
"      Mairesse GH, Marwick TH, Vanoverschelde JL, et al. How accurate is dobutamine stress electrocardiography for detection of coronary artery disease? Comparison with two-dimensional echocardiography and technetium-99m methoxyl isobutyl isonitrile (mibi) perfusion scintigraphy. J Am Coll Cardiol 1994; 24:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/9\">",
"      Metz LD, Beattie M, Hom R, et al. The prognostic value of normal exercise myocardial perfusion imaging and exercise echocardiography: a meta-analysis. J Am Coll Cardiol 2007; 49:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/10\">",
"      Olmos LI, Dakik H, Gordon R, et al. Long-term prognostic value of exercise echocardiography compared with exercise 201Tl, ECG, and clinical variables in patients evaluated for coronary artery disease. Circulation 1998; 98:2679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/11\">",
"      Bavelaar-Croon CD, Pauwels EK, van der Wall EE. Gated single-photon emission computed tomographic myocardial imaging: a new tool in clinical cardiology. Am Heart J 2001; 141:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/12\">",
"      Chua T, Kiat H, Germano G, et al. Gated technetium-99m sestamibi for simultaneous assessment of stress myocardial perfusion, postexercise regional ventricular function and myocardial viability. Correlation with echocardiography and rest thallium-201 scintigraphy. J Am Coll Cardiol 1994; 23:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/13\">",
"      Chuah SC, Pellikka PA, Roger VL, et al. Role of dobutamine stress echocardiography in predicting outcome in 860 patients with known or suspected coronary artery disease. Circulation 1998; 97:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/14\">",
"      Lee TH, Boucher CA. Clinical practice. Noninvasive tests in patients with stable coronary artery disease. N Engl J Med 2001; 344:1840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/15\">",
"      Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002; 106:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/16\">",
"      DePuey EG, Rozanski A. Using gated technetium-99m-sestamibi SPECT to characterize fixed myocardial defects as infarct or artifact. J Nucl Med 1995; 36:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/17\">",
"      Johnson LL, Verdesca SA, Aude WY, et al. Postischemic stunning can affect left ventricular ejection fraction and regional wall motion on post-stress gated sestamibi tomograms. J Am Coll Cardiol 1997; 30:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/18\">",
"      Borges-Neto S, Javaid A, Shaw LK, et al. Poststress measurements of left ventricular function with gated perfusion SPECT: comparison with resting measurements by using a same-day perfusion-function protocol. Radiology 2000; 215:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/19\">",
"      Hendel RC, Berman DS, Cullom SJ, et al. Multicenter clinical trial to evaluate the efficacy of correction for photon attenuation and scatter in SPECT myocardial perfusion imaging. Circulation 1999; 99:2742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/20\">",
"      Hendel RC, Corbett JR, Cullom SJ, et al. The value and practice of attenuation correction for myocardial perfusion SPECT imaging: a joint position statement from the American Society of Nuclear Cardiology and the Society of Nuclear Medicine. J Nucl Cardiol 2002; 9:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/21\">",
"      Mahmarian JJ, Verani MS. Exercise thallium-201 perfusion scintigraphy in the assessment of coronary artery disease. Am J Cardiol 1991; 67:2D.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/22\">",
"      Fintel DJ, Links JM, Brinker JA, et al. Improved diagnostic performance of exercise thallium-201 single photon emission computed tomography over planar imaging in the diagnosis of coronary artery disease: a receiver operating characteristic analysis. J Am Coll Cardiol 1989; 13:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/23\">",
"      Beller GA, Zaret BL. Contributions of nuclear cardiology to diagnosis and prognosis of patients with coronary artery disease. Circulation 2000; 101:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/24\">",
"      Hlatky MA, Pryor DB, Harrell FE Jr, et al. Factors affecting sensitivity and specificity of exercise electrocardiography. Multivariable analysis. Am J Med 1984; 77:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/25\">",
"      Iskandrian AS, Heo J, Kong B, Lyons E. Effect of exercise level on the ability of thallium-201 tomographic imaging in detecting coronary artery disease: analysis of 461 patients. J Am Coll Cardiol 1989; 14:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/26\">",
"      Heller GV, Ahmed I, Tilkemeier PL, et al. Influence of exercise intensity on the presence, distribution, and size of thallium-201 defects. Am Heart J 1992; 123:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/27\">",
"      Iskandrian AS, Heo J, Kong B, et al. Use of technetium-99m isonitrile (RP-30A) in assessing left ventricular perfusion and function at rest and during exercise in coronary artery disease, and comparison with coronary arteriography and exercise thallium-201 SPECT imaging. Am J Cardiol 1989; 64:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/28\">",
"      Kahn JK, McGhie I, Akers MS, et al. Quantitative rotational tomography with 201Tl and 99mTc 2-methoxy-isobutyl-isonitrile. A direct comparison in normal individuals and patients with coronary artery disease. Circulation 1989; 79:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/29\">",
"      Kiat H, Van Train KF, Maddahi J, et al. Development and prospective application of quantitative 2-day stress-rest Tc-99m methoxy isobutyl isonitrile SPECT for the diagnosis of coronary artery disease. Am Heart J 1990; 120:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/30\">",
"      Taillefer R, DePuey EG, Udelson JE, et al. Comparative diagnostic accuracy of Tl-201 and Tc-99m sestamibi SPECT imaging (perfusion and ECG-gated SPECT) in detecting coronary artery disease in women. J Am Coll Cardiol 1997; 29:69.",
"     </a>",
"    </li>",
"    <li>",
"     Maddahi J, Kiat H, Friedman JD, et al. Technetium-99m-sestamibi myocardial perfusion imaging for evaluation of coronary artery disease. In: Nuclear Cardiology: State of the Art and Future Directions, 1st ed, Zaret BL, Beller GA (Eds), Mosby-Year Book, St. Louis 1993. p.191.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/32\">",
"      Berman DS, Kiat H, Friedman JD, et al. Separate acquisition rest thallium-201/stress technetium-99m sestamibi dual-isotope myocardial perfusion single-photon emission computed tomography: a clinical validation study. J Am Coll Cardiol 1993; 22:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/33\">",
"      McClellan JR, Travin MI, Herman SD, et al. Prognostic importance of scintigraphic left ventricular cavity dilation during intravenous dipyridamole technetium-99m sestamibi myocardial tomographic imaging in predicting coronary events. Am J Cardiol 1997; 79:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/34\">",
"      Udelson JE, Coleman PS, Metherall J, et al. Predicting recovery of severe regional ventricular dysfunction. Comparison of resting scintigraphy with 201Tl and 99mTc-sestamibi. Circulation 1994; 89:2552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/35\">",
"      Kauffman GJ, Boyne TS, Watson DD, et al. Comparison of rest thallium-201 imaging and rest technetium-99m sestamibi imaging for assessment of myocardial viability in patients with coronary artery disease and severe left ventricular dysfunction. J Am Coll Cardiol 1996; 27:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/36\">",
"      Cerqueira MD, Allman KC, Ficaro EP, et al. Recommendations for reducing radiation exposure in myocardial perfusion imaging. J Nucl Cardiol 2010; 17:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/37\">",
"      Des Prez, et al. ASNC Clinical Update: Stress-only myocardial perfusion imaging. J Nucl Cardiol 2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/38\">",
"      Bhavnani SP, Heller GV. Stress-only myocardial perfusion imaging &hellip; it is time for a change! J Nucl Cardiol 2011; 18:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/39\">",
"      Singh B, Bateman TM, Case JA, Heller G. Attenuation artifact, attenuation correction, and the future of myocardial perfusion SPECT. J Nucl Cardiol 2007; 14:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/40\">",
"      Heller GV, Bateman TM, Johnson LL, et al. Clinical value of attenuation correction in stress-only Tc-99m sestamibi SPECT imaging. J Nucl Cardiol 2004; 11:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/41\">",
"      Gibson PB, Demus D, Noto R, et al. Low event rate for stress-only perfusion imaging in patients evaluated for chest pain. J Am Coll Cardiol 2002; 39:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/42\">",
"      Maddahi J, Abdulla A, Garcia EV, et al. Noninvasive identification of left main and triple vessel coronary artery disease: improved accuracy using quantitative analysis of regional myocardial stress distribution and washout of thallium-201. J Am Coll Cardiol 1986; 7:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/43\">",
"      Iskandrian AS, Heo J, Lemlek J, Ogilby JD. Identification of high-risk patients with left main and three-vessel coronary artery disease using stepwise discriminant analysis of clinical, exercise, and tomographic thallium data. Am Heart J 1993; 125:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/44\">",
"      Kwok JM, Christian TF, Miller TD, et al. Identification of severe coronary artery disease in patients with a single abnormal coronary territory on exercise thallium-201 imaging: the importance of clinical and exercise variables. J Am Coll Cardiol 2000; 35:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/45\">",
"      Vaduganathan P, He ZX, Raghavan C, et al. Detection of left anterior descending coronary artery stenosis in patients with left bundle branch block: exercise, adenosine or dobutamine imaging? J Am Coll Cardiol 1996; 28:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/46\">",
"      Yao SS, Rozanski A. Principal uses of myocardial perfusion scintigraphy in the management of patients with known or suspected coronary artery disease. Prog Cardiovasc Dis 2001; 43:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/47\">",
"      Snader CE, Marwick TH, Pashkow FJ, et al. Importance of estimated functional capacity as a predictor of all-cause mortality among patients referred for exercise thallium single-photon emission computed tomography: report of 3,400 patients from a single center. J Am Coll Cardiol 1997; 30:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/48\">",
"      Diaz LA, Brunken RC, Blackstone EH, et al. Independent contribution of myocardial perfusion defects to exercise capacity and heart rate recovery for prediction of all-cause mortality in patients with known or suspected coronary heart disease. J Am Coll Cardiol 2001; 37:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/49\">",
"      Lauer MS, Francis GS, Okin PM, et al. Impaired chronotropic response to exercise stress testing as a predictor of mortality. JAMA 1999; 281:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/50\">",
"      Hachamovitch R, Berman DS, Shaw LJ, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction. Circulation 1998; 97:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/51\">",
"      Parisi AF, Hartigan PM, Folland ED. Evaluation of exercise thallium scintigraphy versus exercise electrocardiography in predicting survival outcomes and morbid cardiac events in patients with single- and double-vessel disease. Findings from the Angioplasty Compared to Medicine (ACME) Study. J Am Coll Cardiol 1997; 30:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/52\">",
"      Hachamovitch R, Berman DS, Kiat H, et al. Value of stress myocardial perfusion single photon emission computed tomography in patients with normal resting electrocardiograms: an evaluation of incremental prognostic value and cost-effectiveness. Circulation 2002; 105:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/53\">",
"      Vanzetto G, Ormezzano O, Fagret D, et al. Long-term additive prognostic value of thallium-201 myocardial perfusion imaging over clinical and exercise stress test in low to intermediate risk patients : study in 1137 patients with 6-year follow-up. Circulation 1999; 100:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/54\">",
"      Brown KA, Rowen M. Prognostic value of a normal exercise myocardial perfusion imaging study in patients with angiographically significant coronary artery disease. Am J Cardiol 1993; 71:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/55\">",
"      Gibbons RJ, Hodge DO, Berman DS, et al. Long-term outcome of patients with intermediate-risk exercise electrocardiograms who do not have myocardial perfusion defects on radionuclide imaging. Circulation 1999; 100:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/56\">",
"      Poornima IG, Miller TD, Christian TF, et al. Utility of myocardial perfusion imaging in patients with low-risk treadmill scores. J Am Coll Cardiol 2004; 43:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/57\">",
"      Schalet BD, Kegel JG, Heo J, et al. Prognostic implications of normal exercise SPECT thallium images in patients with strongly positive exercise electrocardiograms. Am J Cardiol 1993; 72:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/58\">",
"      Raiker K, Sinusas AJ, Wackers FJ, Zaret BL. One-year prognosis of patients with normal planar or single-photon emission computed tomographic technetium 99m-labeled sestamibi exercise imaging. J Nucl Cardiol 1994; 1:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/59\">",
"      Brown KA. Prognostic value of thallium-201 myocardial perfusion imaging. A diagnostic tool comes of age. Circulation 1991; 83:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/60\">",
"      Pavin D, Delonca J, Siegenthaler M, et al. Long-term (10 years) prognostic value of a normal thallium-201 myocardial exercise scintigraphy in patients with coronary artery disease documented by angiography. Eur Heart J 1997; 18:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/61\">",
"      Hachamovitch R, Hayes S, Friedman JD, et al. Determinants of risk and its temporal variation in patients with normal stress myocardial perfusion scans: what is the warranty period of a normal scan? J Am Coll Cardiol 2003; 41:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/62\">",
"      Shaw LJ, Hendel R, Borges-Neto S, et al. Prognostic value of normal exercise and adenosine (99m)Tc-tetrofosmin SPECT imaging: results from the multicenter registry of 4,728 patients. J Nucl Med 2003; 44:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/63\">",
"      Gill JB, Ruddy TD, Newell JB, et al. Prognostic importance of thallium uptake by the lungs during exercise in coronary artery disease. N Engl J Med 1987; 317:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/64\">",
"      Nishimura S, Mahmarian JJ, Verani MS. Significance of increased lung thallium uptake during adenosine thallium-201 scintigraphy. J Nucl Med 1992; 33:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/65\">",
"      Leslie WD, Tully SA, Yogendran MS, et al. Prognostic value of lung sestamibi uptake in myocardial perfusion imaging of patients with known or suspected coronary artery disease. J Am Coll Cardiol 2005; 45:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/66\">",
"      Cerci MS, Cerci JJ, Cerci RJ, et al. Myocardial perfusion imaging is a strong predictor of death in women. JACC Cardiovasc Imaging 2011; 4:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/67\">",
"      Sharir T, Germano G, Kavanagh PB, et al. Incremental prognostic value of post-stress left ventricular ejection fraction and volume by gated myocardial perfusion single photon emission computed tomography. Circulation 1999; 100:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/68\">",
"      Hachamovitch R, Berman DS, Kiat H, et al. Exercise myocardial perfusion SPECT in patients without known coronary artery disease: incremental prognostic value and use in risk stratification. Circulation 1996; 93:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/69\">",
"      Hachamovitch R, Hayes SW, Friedman JD, et al. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003; 107:2900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/70\">",
"      Mieres JH, Shaw LJ, Hendel RC, et al. American Society of Nuclear Cardiology consensus statement: Task Force on Women and Coronary Artery Disease--the role of myocardial perfusion imaging in the clinical evaluation of coronary artery disease in women [correction]. J Nucl Cardiol 2003; 10:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/71\">",
"      Haffner SM, Lehto S, R&ouml;nnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/72\">",
"      Kang X, Berman DS, Lewin HC, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography in patients with diabetes mellitus. Am Heart J 1999; 138:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/73\">",
"      Giri S, Shaw LJ, Murthy DR, et al. Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease. Circulation 2002; 105:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/24/24970/abstract/74\">",
"      Vanzetto G, Halimi S, Hammoud T, et al. Prediction of cardiovascular events in clinically selected high-risk NIDDM patients. Prognostic value of exercise stress test and thallium-201 single-photon emission computed tomography. Diabetes Care 1999; 22:19.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5306 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-09444732DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_24_24970=[""].join("\n");
var outline_f24_24_24970=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHOICE OF TEST MODALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Comparison of test performance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prediction of event-free survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Summary and ACC/AHA guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TECHNICAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Study protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Choice of isotope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Attenuation artifacts and correction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EXERCISE RMPI FOR DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Test performance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Exercise level",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - 201-Tl versus 99m-Tc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Dual versus single isotope imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Left main coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Special settings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - LBBB or paced ventricular rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      EXERCISE RMPI FOR PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Normal rMPI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - With exercise ECG testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Abnormal rMPI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      EXERCISE RMPI FOR CHOICE OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      EXERCISE RMPI IN WOMEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      EXERCISE RMPI IN DIABETES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5306\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5306|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?26/52/27470\" title=\"algorithm 1\">",
"      Choice stress test modality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?23/60/24512\" title=\"algorithm 2\">",
"      Algorithm ETT angio chest pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?32/5/32862\" title=\"algorithm 3\">",
"      Maximal reduction in patient radiation exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?18/47/19199\" title=\"algorithm 4\">",
"      Evaluation of women for CAD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5306|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/13/36062\" title=\"figure 1\">",
"      Exercise thallium predictors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/40/20110\" title=\"figure 2\">",
"      SPECT imaging and outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/5/10334\" title=\"figure 3\">",
"      Dual isotope MPI prognosis CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/1/34845\" title=\"figure 4\">",
"      Diabetes increases coronary mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5306|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/42/18093\" title=\"table 1\">",
"      ACC AHA choice imaging CHD diagnosis able to exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/46/33516\" title=\"table 2\">",
"      ACC AHA choice imaging risk I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/8/6284\" title=\"table 3\">",
"      Pretest probability of CHD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23066?source=related_link\">",
"      Assessment of myocardial viability by nuclear imaging in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/10/25768?source=related_link\">",
"      Attenuation artifact in SPECT radionuclide myocardial perfusion imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8759?source=related_link\">",
"      Clinical syndromes of stunned or hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=related_link\">",
"      Exercise ECG testing to determine prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=related_link\">",
"      Medical therapy versus revascularization in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=related_link\">",
"      Performance of exercise ECG testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=related_link\">",
"      Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6678?source=related_link\">",
"      Radionuclide myocardial perfusion imaging in predischarge risk stratification of medically treated patients with non-ST elevation acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18761?source=related_link\">",
"      Screening for coronary heart disease in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/30/44520?source=related_link\">",
"      Selecting the optimal cardiac stress test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=related_link\">",
"      Stress echocardiography in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=related_link\">",
"      Stress testing for the diagnosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28743?source=related_link\">",
"      Stress testing in patients with left bundle branch block or a paced ventricular rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=related_link\">",
"      Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=related_link\">",
"      Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_24_24971="fFN perform sx and asx women";
var content_f24_24_24971=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Fetal fibronectin and risk of preterm birth",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Population/delivery",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Summary likelihood ratios (95 percent CI)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Negative test result",
"       </td>",
"       <td class=\"subtitle2\">",
"        Positive test result",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Asymptomatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Before 34 weeks",
"       </td>",
"       <td>",
"        0.78 (0.72 to 0.84)",
"       </td>",
"       <td>",
"        4.01 (2.93 to 5.49)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Before 37 weeks",
"       </td>",
"       <td>",
"        0.52 (0.44 to 0.62)",
"       </td>",
"       <td>",
"        2.94 (2.47 to 3.50)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Symptomatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Within 7-10 days",
"       </td>",
"       <td>",
"        0.25 (0.20 to 0.31)",
"       </td>",
"       <td>",
"        5.42 (4.36 to 6.74)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Before 34 weeks",
"       </td>",
"       <td>",
"        0.32 (0.16 to 0.66)",
"       </td>",
"       <td>",
"        3.64 (2.32 to 5.73)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Before 37 weeks",
"       </td>",
"       <td>",
"        0.48 (0.41 to 0.56)",
"       </td>",
"       <td>",
"        3.27 (2.74 to 3.92)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Honest, H, Bachmann, LM, Gupta, JK. BMJ 2002; 325:301.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_24_24971=[""].join("\n");
var outline_f24_24_24971=null;
var title_f24_24_24972="Causes of TVL";
var content_f24_24_24972=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F64994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F64994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Typical features of common causes of transient visual loss",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Etiology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Typical duration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pattern of visual loss",
"       </td>",
"       <td class=\"subtitle1\">",
"        Associated symptoms and signs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monocular ischemia, carotid disease, other embolic source",
"       </td>",
"       <td>",
"        1 to 10 minutes",
"       </td>",
"       <td>",
"        Monocular, rapid onset, altitudinal onset",
"       </td>",
"       <td>",
"        Hollenhorst plaque, hemispheric symptoms",
"       </td>",
"       <td>",
"        Retinal embolism (usually)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Giant Cell arteritis",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"       <td>",
"        Usually monocular",
"       </td>",
"       <td>",
"        Headache, neck pain, jaw claudication",
"       </td>",
"       <td>",
"        Ischemia of optic nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Papilledema",
"       </td>",
"       <td>",
"        Seconds",
"       </td>",
"       <td>",
"        Monocular graying or blurring",
"       </td>",
"       <td>",
"        Headache, diplopia",
"       </td>",
"       <td>",
"        Elevated intracranial pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic retinal vasospasm",
"       </td>",
"       <td>",
"        5 to 60 minutes",
"       </td>",
"       <td>",
"        Monocular positive or negative symptoms",
"       </td>",
"       <td>",
"        Transient retinal arterial narrowing, headache",
"       </td>",
"       <td>",
"        Vasospasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Migraine",
"       </td>",
"       <td>",
"        10 to 30 minutes",
"       </td>",
"       <td>",
"        Usually binocular, positive symptoms with spread",
"       </td>",
"       <td>",
"        Usually followed by migraine headache",
"       </td>",
"       <td>",
"        Spreading cortical depression, possibly retinal vasospasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vertebrobasilar ischemia",
"       </td>",
"       <td>",
"        1 to 10 minutes",
"       </td>",
"       <td>",
"        Homonymous hemianopia",
"       </td>",
"       <td>",
"        Isolated or accompanied by other brainstem deficits",
"       </td>",
"       <td>",
"        Embolic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seizure: Ictal",
"       </td>",
"       <td>",
"        3 to 5 minutes",
"       </td>",
"       <td>",
"        Binocular, lateralized, positive phenomenon common",
"       </td>",
"       <td>",
"        Altered consciousness, motor symptoms",
"       </td>",
"       <td>",
"        Epileptic discharge",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postictal",
"       </td>",
"       <td>",
"        20 minutes, longer",
"       </td>",
"       <td>",
"        Binocular visual field loss",
"       </td>",
"       <td>",
"        Preceding ictus",
"       </td>",
"       <td>",
"        Cortical inhibition",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_24_24972=[""].join("\n");
var outline_f24_24_24972=null;
var title_f24_24_24973="Second line TB drugs for children";
var content_f24_24_24973=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F88543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F88543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dosing of second line antituberculosis drugs in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Daily pediatric dosage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maximum daily dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Main adverse affects",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Levofloxacin*",
"       </td>",
"       <td>",
"        <p>",
"         Age &ge;5 years: 7.5 to 10 mg/kg orally",
"        </p>",
"        Age &lt;5 years: 15 to 20 mg/kg orally in two divided doses*",
"       </td>",
"       <td>",
"        750 mg*",
"       </td>",
"       <td rowspan=\"3\">",
"        GI toxicity, sleep disturbance, arthritis, CNS-headache, peripheral neuropathy, QT prolongation (moxifloxacin &gt; levofloxacin)",
"       </td>",
"       <td rowspan=\"3\">",
"        Potential choice when there are no suitable alternatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moxifloxacin*",
"       </td>",
"       <td>",
"        7.5 to 10 mg/kg orally*",
"       </td>",
"       <td>",
"        400 mg*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ofloxacin*",
"       </td>",
"       <td>",
"        15 to 20 mg/kg orally in two divided doses*",
"       </td>",
"       <td>",
"        800 mg*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Capreomycin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        15 to 30 mg/kg IM or IV",
"       </td>",
"       <td>",
"        1 g",
"       </td>",
"       <td>",
"        Auditory and vestibular toxicity, nephrotoxicity, electrolyte disturbances",
"       </td>",
"       <td>",
"        Avoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kanamycin",
"        <sup>",
"         &bull;",
"        </sup>",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        15 to 30 mg/kg IM or IV",
"       </td>",
"       <td>",
"        1 g",
"       </td>",
"       <td>",
"        Ototoxicity, nephrotoxicity",
"       </td>",
"       <td>",
"        Avoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amikacin",
"        <sup>",
"         &bull;",
"        </sup>",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        15 to 22.5 mg/kg IM or IV",
"       </td>",
"       <td>",
"        1 g",
"       </td>",
"       <td>",
"        Ototoxicity, nephrotoxicity",
"       </td>",
"       <td>",
"        Avoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Streptomycin",
"        <sup>",
"         &bull;",
"        </sup>",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        15 to 30 mg/kg IM or IV",
"       </td>",
"       <td>",
"        1 g",
"       </td>",
"       <td>",
"        Vestibular and ototoxicity, neurotoxicity, nephrotoxicity",
"       </td>",
"       <td>",
"        Avoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethionamide",
"       </td>",
"       <td>",
"        15 to 20 mg/kg orally in two divided doses",
"       </td>",
"       <td>",
"        1 g",
"       </td>",
"       <td>",
"        <p>",
"         GI and hepatic toxicity, neurotoxicity, hypothyroidism, optic neuritis, metallic taste.",
"        </p>",
"        Pyridoxine 50 to 100 mg orally per day may be useful in preventing or reducing neurotoxicity.",
"       </td>",
"       <td>",
"        Potential choice when there are no suitable alternatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cycloserine",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        10 to 20 mg/kg orally in two divided doses",
"       </td>",
"       <td>",
"        1 g",
"       </td>",
"       <td>",
"        <p>",
"         Psychiatric symptoms, headaches, seizures.",
"        </p>",
"        Pyridoxine 50 mg (oral once per day) for every 250 mg of cycloserine may be useful in preventing or reducing neurotoxicity.",
"       </td>",
"       <td>",
"        Potential choice when there are no suitable alternatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Para-aminosalicylic acid",
"       </td>",
"       <td>",
"        150 mg/kg orally in two or three divided doses",
"       </td>",
"       <td>",
"        12 g",
"       </td>",
"       <td>",
"        GI toxicity, malabsorption, hypersensitivity, hepatitis, hypothyroidism",
"       </td>",
"       <td>",
"        Potential choice when there are no suitable alternatives",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TB: tuburculosis; IM: intramuscular; IV: intravenous; GI: gastrointestinal; CNS: central nervous system; max: maximum.",
"     <br/>",
"     * According to the American Academy of Pediatrics, although fluoroquinolones are generally contraindicated in children &lt;18 years old, their use may be justified in certain circumstances, such as multidrug-resistant tuberculosis. The optimal dose is not known.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Generally given five to seven times per week (15 mg/kg, or a maximum of 1 g per dose) for an initial two to four months, and then (if needed) two to three times per week (20 to 30 mg/kg, or a maximum of 1.5 g per dose). Dosage should be decreased if renal function is diminished.",
"     <br/>",
"     &Delta; For patients who are overweight or obese, dose is based on ideal body weight or dosing weight (see UpToDate calculator). When available, serum drug monitoring is advised to establish optimal dosing.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     When available, serum drug monitoring is advised to establish optimal dosing. Recommended peak (two to four hours post-dose) level is not higher than 30 microg/mL.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Seddon J, et al. Caring for children with drug-resistant tuberculosis: practice-based recommendations. Am J Respir Crit Care Med 2012; 186:953.",
"      </li>",
"      <li>",
"       Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva, World Health Organization, 2008.",
"      </li>",
"     </ol>",
"     <br/>",
"     Adapted with special permission from: Treatment Guidelines from The Medical Letter, April 2012; Vol. 10 (116):29.",
"     <a href=\"file://www.medicalletter.org\" target=\"_blank\">",
"      www.medicalletter.org",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_24_24973=[""].join("\n");
var outline_f24_24_24973=null;
var title_f24_24_24974="Efficacy of darbepoetin alpha";
var content_f24_24_24974=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F73640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F73640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Graph showing efficacy of darbepoetin alfa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 348px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Darbepoetin alfa administered at an extended dosing interval effectively maintains Hb levels in patients converted from rHuEPO. Values shown are mean (&plusmn;2 SD) Hb concentrations by study week. Dialysis patients undergoing hemodialysis received recombinant human erythropoietin (rHuEPO) three times weekly or were converted to a once-weekly regimen of darbepoetin alfa titrated to maintain Hb levels between 9 and 13 g/dL as well as within -1 to +1.5 g/dL of a patient's baseline levels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Nissenson, AR, Swan, SK, Lindberg, JS, et al. Am J Kidney Dis 2002; 40:110.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_24_24974=[""].join("\n");
var outline_f24_24_24974=null;
var title_f24_24_24975="Gram stain sputum 12D answer";
var content_f24_24_24975=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aspergillus fumigatus on Sabouraud's agar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 345px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Aspergillus fumigatus growing on Sabouraud's agar.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_24_24975=[""].join("\n");
var outline_f24_24_24975=null;
